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Abstract 
In recent years, marine natural products have gained attention from scientists within diverse 
research fields, such as biology, pharmacology, medicine and chemistry. Among those natural 
products, several polyunsaturated fatty acids (PUFAs) and their metabolites have been 
isolated. 
This prompted us to develop an efficient synthesis of analogs of the two PUFA marine natural 
products mycalazol 5 and mycalazal 2 starting from eicosapentaenoic acid (EPA) and 
eicosanoic acid (EA). The biological studies revealed that all synthesized analogs displayed 
potent cytotoxic effect against several human cancer cell lines. 
In continuation of this study, another PUFA derived marine natural product was used as a lead 
compound for making analogs that were subjected to biological testing as antioxidants. The 
analogs with a polyunsaturated alkyl chain exhibited more potent effects than the analogs 
possessing a saturated alkyl chain. 
Bosseopentaenoic acid (BPA) and its methyl ester have been isolated from different algae. 
This PUFA contains a (Z,E,E,Z)-conjugated polyene moiety with five double bonds in total. 
An efficient stereocontrolled synthesis of this natural product has been achieved. 
During the work towards the total synthesis of BPA, a Z-stereoselective Boland reduction 
reaction was needed. The Boland reduction procedure was modified by the addition of 
TMSCl, which resulted in shorter reaction times. This procedure was applied for the 
preparation of several Z-alkenes. 
As a continuation of the synthetic work towards BPA, the synthesis of α-parinaric acid was 
also investigated. As in the case with BPA, this naturally occurring PUFA also contains a 
Z,E,E,Z-conjugated polyene moiety, that we attempted to prepare via iterative palladium-
catalyzed cross coupling reactions. 
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1. Introduction 
1.1. Lipids and fatty acids 
The natural products within the class of lipids constitute a wide range of compounds with 
diverse chemical structures. Traditionally, lipids have been defined as organic compounds 
that are soluble in a lipophilic solvent, such as chloroform or ether.1 Recently, however, 
lipids have been defined as “hydrophobic or amphipathic small molecules that may originate 
entirely or in part by carbanion based condensations of thioesters and/or by carbocation-
based condensations of isoprene units”.2 Among the eight classes of naturally occurring 
compounds defined as lipids according to this new definition, the class of fatty acyls or fatty 
acids is a central one.1 Chemically, fatty acids are hydrocarbons attached to a carboxylic acid 
which possess a long aliphatic chain which is either saturated or unsaturated.3 
Among the many unsaturated fatty acids found in nature, the ω-3 and ω-6 
polyunsaturated fatty acids (PUFAs) have received a great interest from scientists in biology, 
medicine and chemistry.4 
 
1.2. ω-3 and ω-6 polyunsaturated fatty acids (PUFAs) 
PUFAs are common in higher organisms and exhibit interesting biological activities. In 
particular, the PUFAs are characterized by the presence of several methylene interrupted 
double bonds, i.e. those with two or more cis-configured double bonds isolated by a single 
methylene group. PUFAs have received a lot of interest over the last fifty years.5,6,7 There are 
four families of polyunsaturated fatty acids, namely ω-9, ω-7, ω-6 and ω-3 PUFAs.8 Oleic 
acid (1) is the precursor of the ω-9 family and palmitoleic acid (2) is the precursor of the ω-7 
family. 
 
Figure 1.1. The chemical structures of the primary precursors molecules for the PUFA families. 
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Oleic acid (1) and palmitoleic acid (2) are non-essential fatty acids that are synthesized in the 
human body from dietary precursors. The two principal families of polyunsaturated fatty 
acids that occur in nature are derived biosynthetically from α-linolenic acid (3, 9Z,12Z,15Z-
octadecatrienoic acid) and linoleic acid (4, 9Z,12Z-octadecadienoic acid). The acids 3 and 4 
are the primary precursor molecules for the ω-3 and ω-6 families, respectively.9  
 
Figure 1.2. An overview of the PUFAs families. 
α-Linolenic (ALA, 3) and linoleic (LA, 4) acids are converted to their respective metabolites 
by a series of alternating desaturation and elongation reactions.10,11 The desaturation reaction 
adds one double bond by removing two atoms of hydrogen, while the elongation reaction 
adds two carbon atoms. The main pathway to the formation of docosahexaenoic acid (DHA, 
9, 22:6, ω-3) requires a sequence of chain elongation and desaturation steps (Δ5 and Δ6 
desaturases with acyl-coenzyme-A esters as substrates)12,13 as illustrated in Scheme 1.1. Thus, 
α-linolenic (3) is sequentially elongated and desaturated with double bonds being inserted 
between existing double bonds and carboxyl group to form eicosapetaenoic acid (EPA, 7, 
20:5, ω-3) which is the precursor of DHA (9) (Scheme 1.1).14 Linoleic acid (4) is the 
precursor for γ-linolenic acid (10, 18:3, ω-6). The first step involves desaturation with 
introduction of a double bond in position 6 to form γ-linolenic acid (10). Chain elongation by 
a two carbon unit gives dihomo γ-linolenic acid (11, 20:3, ω-6), which is converted to 
arachidonic acid (12) by Δ5 desaturase. Arachidonic acid (12) is a metabolite of linoleic acid 
(4) and is considered an essential fatty acid only when linoleic acid deficiency exists.15 
However, two further chain elongation steps yield first docosatetraenoic acid (13, 22:4, ω-
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6),16 which can be further desaturated by a Δ6 desaturase to osbond acid (14, 22:5, ω-6) 
(Scheme 1.1).17  
 
Scheme 1.1.The elongation and desaturation of linoleic acid (3) and α-linolenic acid (4) to PUFAs. 
1.3. Conjugated polyunsaturated fatty acids 
Conjugated fatty acids are polyunsaturated fatty acids in which at least one pair of double 
bonds are separated only by one single bond, as in conjugated linoleic acid (CLA, 15), (Figure 
1.3). Conjugated linoleic acid has been reported to have many beneficial medical effects,18-22 
especially anticancer activity.23-30 Fatty acids with a conjugated triene systems have been 
found in a large number of different plant species. α-Eleostearic acid (16, 18:3, ω-
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5), conjugated EPA (CEPA, 17, 20:5, ω-3) and conjugated DHA (CDHA, 18, 22:5, ω-3) are 
the most widespread and best known.31,32  
 
Figure 1.3. Conjugated diene and triene polyunsaturated fatty acids. 
In 1933, Tsujimoto and Koyanagi isolated α-parinaric acid (19,18:4, ω-3) from the seed oil of 
Parinarium laurinum.33 α-Parinaric acid (19) is a (Z,E,E,Z) conjugated tetraene fatty acid and 
is commonly used as a molecular probe in the study of biomembranes due to the 
fluorescent properties conferred by the alternating double bonds.34  
 
Figure 1.4. Conjugated tetraene polyunsaturated fatty acids. 
Bosseopentaenoic acid (BPA, 20, 5Z,8Z,10E,12E,14Z-eicosapentaenoic, 20:5, ω-6) is also a 
(Z,E,E,Z) conjugated tetraene fatty acid that has been isolated from several algea.35-37 In 
1995, Jacobs and co-workers37 isolated stellaheptaenoic acid (21, 
4Z,7Z,9E,11E,13Z,16Z,19Z-docosaheptaenoic acid, 22:7, ω-3) which is a unique (Z,E,E,Z)  
conjugated tetraene fatty acid with seven double bonds in total. 
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1.4. Biological role of ω-3 and ω-6 polyunsaturated fatty acids 
The ω-3 and ω-6 PUFAs play an important role in health and treatment of diseases. They can 
act as antibacterial agents,38-40 anti-inflammatory agents,41-42 antioxidants,43 in the treatment of 
cardiovascular diseases44 and cancer cell proliferation.45,46 Such properties are indicative of 
the potential for PUFAs as nutraceuticals and as pharmaceuticals. The (ω-3/ω-6) ratio can 
significantly influence the body’s  metabolic function,47 where an increased intake of 
ω-3 PUFAs leads to the replacement of ω-6 PUFAs in cells and tissues resulting in a 
reduction of the overall ω-3/ω-6 ratio. Also a reduction of arachidonic acid (12) derived 
metabolites has been observed. Dietary intake of ω-3 fatty acids may prevent the development 
of disease. An excessive amounts of ω-6 PUFAs (a very high ω-6/ω-3 ratio) promote the 
pathogenesis of many diseases, including cardiovascular disease, cancer, as well as 
inflammatory and autoimmune diseases,48-50 whereas increased levels of ω-3 PUFAs (a low 
ω-6/ω-3 ratio) exert suppressive effects. Clinical studies indicate that increased intake of ω-3 
PUFAs appear to reduce mortality from cardiovascular disease. So it is essential to increase 
the ω-3 PUFAs and decrease the ω-6 PUFAs intake in order to reduce the risk of many of the 
chronic diseases.49,50 
Eicosapentaenoic acid (EPA, 7) and docosahexaenoic acid (DHA, 9) have the most potent 
anti-inflammatory effects.51 Inflammation is at the base of many chronic diseases, including 
cardiovascular disease, diabetes, arthritis, cancer, osteoporosis, mental health, dry eye disease 
and age-related macular degeneration (Figure 1.5).52 
 
 
 
Figure 1.5. Health benefits of EPA and DHA. 
 
Arachidonic acid (12) has long been known to be involved in the initiation involved in the 
biosynthesis of anti-inflammatory and pro-resolving lipid mediators. These include lipoxins 
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which are formed via transcellular biosynthesis through the sequential actions of 5- and 12-
lipoxogenase.53 EPA (7), DHA (9) and arachidonic acid (12) influence gene expression.54 
 
 
Figure 1.6. Examples of lipid mediators. 
 
The enzymatic oxygenation of EPA and DHA has been investigated intensively by Serhan 
and co-workers.55-57 These studies has led to the identification of novel pro-resolving lipid 
mediators. These include the E-series resolvins derived from EPA (RvE1, RvE2), as well as 
the D-series resolvins (RvD1, RvD2, RvD3, RvD4), the protectins (PD1) derived from 
DHA.58  
1.5. Anticarcinogenic action of non-conjugated and conjugated fatty 
acids 
The ω-3 PUFAs, i.e. α-linolenic acid (ALA, 3), EPA (7) and DHA (9) induce in vitro and in 
vivo cytotoxic activity against different tumor cells.59-61 Conjugated linoleic acid (CLA, 15) 
has also been shown to inhibit the cell proliferation of different cancer cell lines.23-30 
However, recently numerous studies have shown that conjugated eicosapentaenoic acid 
(CEPA, 17) and conjugated docosohexaenoic acid (CDHA, 18) induces apoptosis via lipid 
peroxidation62-66 which provides evidence that the conjugated triene polyunsaturated fatty 
acids (CEPA) and (CDHA) have the strongest cytotoxic effect (Figure 1.7). It was found that 
CEPA and CDHA caused apoptosis via formation of lipid peroxidation products in vivo that 
induce cytotoxic effect. This cytotoxic action were selective for tumor cells causing cell death 
only in tumor cells.65,66 
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Figure 1.7. Anticarcinogenic action of non-conjugated and conjugated PUFAs. 
It is possible that conjugated tetraenes such as bosseopentaenoic acid (BPA, 20) and 
stellaheptaenoic acid 21 induce tumor cell death in the same manner as described for CEPA 
and CDHA. 
1.6. Metabolism of ω-3 and ω-6 PUFAs 
1.6.1. α-Cyclooxygenase and prostaglandins biosynthesis 
In  the late 1980 and 1990s a  series  of discoveries were made that led to the identification of 
two COX enzymes:69-75 COX-1, which is  a constitutively expressed  isoform  involved  in  
physiologic  maintenance  functions,  and  COX-2,  which  is  predominantly  synthesized  in  
response  to  inflammatory stimuli. The  COX  enzyme  has  two  distinct  active  sites, 
respectively  termed  the  cyclooxygenase  active  site and  the  peroxidase  active site. The 
cyclooxygenase site cyclizes arachidonic acid (AA, 12) and adds a hydroperoxy group to 
carbon 15 to form prostaglandin G2 (PGG2, 26) (Figure 1.8). The  separate  peroxidase  site  
of  the  same  COX enzyme then reduces this hydroperoxy group to the hydroxy  group  to  
form prostaglandin H2  (PGH2, 27) (Figure 1.8).69-72 COX-1 and COX-2 have identical 
enzymatic actions, and the synthesis of PGH2 is depending on the tissue where it is 
synthesized.76 
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Figure 1.8. Biosynthetic pathway of prostaglandins. 
COX-2-specific nonsteroidal anti-inflammatory drugs (NSAIDs) are lipophilic organic acids. 
Thus, the lower the pH, the greater is their lipophilicity. This combination of chemical 
properties allows the COX-2-specific NSAIDs (as well as conventional NSAIDs) to cross 
lipid membranes, including the blood-brain barrier, and to accumulate in acidic tissues such 
as the stomach, renal medulla, and sites of inflammation.77 The COX-2 selectivity of NSAIDs 
is defined by the COX-2/COX-1 ratio.78 The larger this ratio, the greater the selectivity of the 
compound is for COX-2. However, this ratio can vary significantly, depending on which of 
the different in vitro and in vivo assays that are used to generate the ratio.78 
1.6.2. Lipoxyganse and leukotriene biosynthesis 
Unlike the cyclooxygenases (COX-1 and COX-2), which are active in most body 
cells, lipoxygenase enzymes are primarily active in cells of the immune system. 
Lipoxygenases are enzymes that catalyse the stereospecific incorporation of molecular 
oxygen into polyunsaturated fatty acids.79 
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5-Lipoxygenase (5-LO) creates hydroperoxide PUFAs by an insertion of molecular oxygen.80 
Leukotriene  biosynthesis depends  upon  the  availability  of arachidonic acid as a free 
carboxylic acid as the 5-LO substrate, which typically requires the  action  of  cytosolic 
phospholipase  A2  to  release  arachidonic  acid  from  membrane phospholipids.81 The name 
leukotriene was conceived to capture two unique attributes of these molecules. The first 
attribute relates to those white blood cells derived from the bone marrow that have the  
capacity to synthesize this  class  of eicosanoid, for example the polymorph nuclear leukocyte.  
The last part of the name refers to the unique chemical structure, a conjugated triene retained 
within these eicosanoids.82 The first step for the leukotriene biosynthesis is the insertion of 
molecular oxygen at position-5 of arachidonic acid (12) to produce 5(S)-hydroperoxy-
eicosatetraenoic acid (5-HPETE, 28) that can be converted to leukotriene A4 (LTA4, 30) by 
the second catalytic activity of 5-lipoxyganse.81 
 
 
Figure 1.9. An overview of the biosynthetic pathway of leukotrienes. 
Leukotriene A4 is the precursor of leukotriene B4 (LTB4, 31) including also leukotrienes 
(LTC4, 32), (LTD4, 33) and (LTE4, 34). Leukotriene B4 is showing chemotactic and  
chemokinetic activity in vivo,83 while LTC4 exhibit potent smooth muscle contracting activity, 
and  mediates  leakage  of  vascular  fluid  in the  process  of edema.84,85 
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12-LO and 15-LO catalyze the transformation of free arachidonic acid (12) to 12(S)-
hydroperoxy-5Z,8Z,9E,13Z-eicosatetraenoic acid (12-HPETE, 35) and 15(S)-hydroperoxy-
5Z,8Z,11Z,13E-eicosatetraenoic acid (15-HPETE, 37). These products are reduced to the 
corresponding hydroxy derivatives 12-HETE 36 and 15-HETE 38 by cellular peroxidases. 
The first step of the biosynthesis of lipoxin A4 (LXA4, 25) and lipoxin B4  (LXB4, 40) is the 
formation of 15-HPETE 35 by a 15-lipoxygenase then reduced by a 5-lipoxygenase to form 
first an epoxy intermediate, i.e. 5S,6S-epoxy-15S-hydroxy-ETE (39) and then, depending on 
the cell type, by specific hydrolases to form either 5S,6R,15S-trihydroxy-7E,9E,13E,11Z-
eicosatetraenoic acid (LXA4, 25), or to 5S,14R,15S-trihydroxy-6E,10E,12E,8Z-eicosa-
tetraenoic acid (LXB4, 40) (Figure 1.10).87 These bioactive trihydroxytetraene containing 
lipid mediators appear to function as stop signals for inflammatory responses and to promote 
repair and wound healing.53 
 
Figure 1.10. Catalytic action of 12/15 LO on arachidonic acid (12) and formation of lipoxins. 
1.7. Some naturally occurring ω-3 and ω-6 PUFAs  
1.7.1. Eicosanoids 
The main eicosanoids are derived from the linoleic series (metabolites of arachidonic acid, 
AA) and of the α-linolenic series (metabolites of eicosapentaenoic acid). The eicosanoids 
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have traditionally been classified into four families (prostaglandins, prostacyclins, 
thromboxanes and leukotrienes).88 
1.7.1.1. Prostaglandins 
The prostaglandins are lipid mediators with physiological effects, such as regulation of the 
contraction and relaxation of smooth muscle tissue. They are synthesized in the cell from 
the essential fatty acids (EFAs). Bergström and Samuelsson isolated and structural elucidated 
the chemical structures of many prostaglandins.89-93 Sir John Vane discovered that aspirin-like 
drugs could inhibit the synthesis of prostaglandins.94-97 Bergström, Samuelsson and Vane 
received the 1982 Nobel Prize in Physiology or Medicine for their research on prostaglandins. 
E. J. Corey reported the first total syntheses of prostaglandin E2 (41) and prostaglandin F2α 
(42) in 1969.98 
The prostaglandins of series-2 are derived from arachidonic acid (12) (Figure 1.11).  
 
Figure 1.11. Biosynthetic pathway of PGE2α and PG F2α. 
The prostaglandins of the 3-series are derived from EPA (7) (Figure 1.12).  
 
Figure 1.12. Biosynthetic pathway of PGE3α and PGF3α. 
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1.7.1.2. Prostacyclin 
Prostacyclin or prostaglandin I2 (PGI2, 46) is produced in endothelial cells from prostaglandin 
H2 (PGH2, 27) by the action of the enzyme prostacyclin synthase (Figure1.13).99 
 
Figure 1.13. Biosynthetic pathway of PGI2. 
1.7.1.3. Thromboxanes 
The two main thromoboxanes are thromboxane A2 (TXA2, 47) and thromboxane B2 (TXB2, 
48), which are characterized by the presences of a 6-membered cyclic ether (Figure 1.14).100 
 
Figure 1.14. Biosynthetic pathway of TXA2 and TXB2. 
1.7.1.4. Leukotrienes 
Samuelsson and co-workers discovered the leukotrienes in white cells derived from bone 
marrow, i.e. leukocytes. These compounds have three double bonds in conjugation. The 
leukotrienes are synthesized in the cell from arachidonic acid (12) by 5-lipoxygenase (Figure 
1.15).80-82 
 
Figure 1.15. Examples of leukotrienes. 
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1.7.2. Polyunsaturated natural products 
Bacillariolide I and its isomer bacillariolide II are unique eicosanoids which have been 
isolated from the wild and cultured cells of the diatom, Pseudo-nitzschia multiseries.101 They 
possess a γ-lactone fused cyclopentanol framework with four stereocenters in addition to four 
methylene-interrupted double bonds (Figure 1.16). Bacillariolide I was reported as an 
inhibitor of phospholipase A2 (PLA2).102 
 
Figure 1.16. The structure of bacillariolides I and II. 
The biosynthesis of bacillariolides seems to be closely related to the leukotriene biosynthesis 
and can be explained by the initial formation of 5(S)-hydropyroxy eicosapentaenoic acid (5-
HPEPE, 51) from EPA (7) which rearranged to the hydroxyl peroxide (52).  The final step 
will then be the carbon ring closure by anionic opening of the epoxide (Figure 1.17).101 
 
Figure 1.17. Biosynthetic pathway of bacillariolides I,II. 
Salvà and co-workers isolated fourteen pyrrole-based metabolites coined mycalazol and 
mycalazal from the sponge Mycale micracanthoxea.103 These natural products contain long 
carbon chain attached to the pyrrole ring at position-5. Some of them contain several 
methylene-interrupted cis-double bonds, i.e.: mycalazol 1 (53) and 2 (54) contain the same 
number of double bonds as in DHA (9) and as in α-linolenic acid (3), respectively. Mycalazol 
5 (55) and mycalazal 2 (56) contain the same number of double bonds as in EPA (7) (Figure 
1.18).  
 
Figure 1.18. Pyrrole-based metabolites. 
 
1. Introduction 
 
14 
 
Platteli and Tringali reported the isolation and structure elucidation of all-(Z)-5,7-dihydroxy-
2-(4Z,7Z,10Z,13Z,16Z-nonadecapentaenyl) chromone (57) from the pacific brown algae 
Zonaria tournefortii.104 This polyunsaturated chromone metabolite possess the same number 
of methylene Z-interrupted double bonds as in EPA (7) (Figure 1.19).  
 
Figure 1.19. Chromone-based metabolite. 
1.8. Stereoselective synthesis of cis-double bonds 
Polyyne-semihydrogenation and Wittig reactions are considered the most two common 
strategies to synthesize polyunsaturated fatty acids and their metabolites.3 
For the polyyne-semihydrogenation sequence, numerous systems have been reported for the 
reduction of a triple bond to a (Z)-double bond. In 1952, Lindlar reported that hydrogenation 
of alkynes under palladium catalysis (palladium oxide deposited on CaCO3 or BaSO4, and 
poisoned with lead acetate and quinoline) led to (Z)-alkenes with high selectivity.105 Brown 
published another selective catalyst in 1973 which is known as the P-2 Ni catalyst. P2-Ni is 
generated in situ by reduction of nickel acetate with sodium borohydride in ethanol.106 Many 
other systems have later been developed for the semi-hydrogenation of alkynes, such as 
triphenyl-phosphine copper hydride developed by Stryker and co-workers,107 and tantalum 
chloride or titanium tetra-isopropoxide isopropyl magnesium chloride system.108 
 
Figure 1.20. The routes for the synthesis of cis-alkenes. 
For the Wittig reaction, the product may be formed as a mixture of cis- and trans-isomers, but 
each of these can be improved by appropriate reaction condition.109 The cis-isomer is the 
dominate product when the reaction is carried out at low temperature (-100 oC), at high 
dilution and absence of lithium. Sodium bis-(trimethylsilyl) amide [NaN(SiMe3)2] is 
recommended as base.3 
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All of the aforementioned described methods have been used for the construction of (Z, Z)-
1,4-dienes which are useful for the synthesis of methylene interrupted PUFAs. However, 
these methods can lead to mixtures of cis- and trans-isomers in the case of conjugated 
systems or highly unsaturated substrates.110 In 1987, Boland and co-workers developed a 
method to activate zinc by mixing it with silver and copper to produce a Zn(Cu/Ag) system.111 
This system is efficient for the reduction of the conjugated alkynes to afford the 
corresponding Z-alkenes (Figure 1.21), but this system showed some limitation in the case of 
sensitive compounds or highly unsaturated compounds.112-114  
 
Figure 1.21. Selective semi-hydrogenation of conjugated alkynes by the Zn(Cu/Ag) system. 
1.9. Synthesis of polyunsaturated fatty acids 
It is well established that PUFAs have an important role in physiology and biochemistry. 
They are precursors for the biosynthesis of eicosanoids and hormone-like signaling molecule. 
However, animal lipids are not practical as starting materials for the preparation of large 
quantities of pure PUFAs required for comprehensive biological and nutritional 
investigations. Hence, synthetic studies are still desirable for this purpose. Herein is the 
different strategies used for the synthesis of PUFAs outlined.  
1.9.1.Synthesis of PUFAs via acetylenic intermediate 
The synthesis of the (Z,Z)-1,4-diene system is initialized by the formation of a skipped diyne 
by reacting a propargyl halide derivative with an alkynyl magensium halide followed by a Z-
stereoselective reduction to the diyne system.3 
The method can be generalized by the following Scheme 1.2. 
 
Scheme 1.2. Construction of the (Z,Z)-1,4-diene system. 
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Linoleic acid (4) was the first PUFA that was synthesized by this approach by Rafael and 
Sondheimer in 1950 (Scheme 1.3).115 
 
Scheme 1.3. The first total synthesis of linoleic acid (4). 
In 1959, Osbond and co-workers synthesized arachidonic acid (AA, 12) based on iterative use of 
propargyl alcohol. This synthetic protocol is considered as a general route to synthesize methylene 
interrupted PUFA (Scheme 1.4).116 Docosahexaenoic acid (9) was also prepared by a similar 
stratgy.117 
 
Scheme1.4. The first total synthesis of arachidonic acid (12). 
1.9.2. Synthesis of PUFAs using the Wittig reaction 
The Wittig reaction is a reaction between a carbonyl compound and a phosphonium halide 
salt. The product can very often be a mixture of cis- and trans-isomers, but each of these can 
be optimized by appropriate reaction condition.109 
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Eicosapentaenoic acid (EPA, 7) was synthesized by employing the C-3 homologating agent 
77.118 The synthesis of EPA started with the first Wittig reaction between C-3 homologating 
agent 77 with aldehyde 82 to afford compound 84 that was reduced by sodium borohydride 
followed by bromination and phosphorylation affording the phoshphonium salt 85. All-(Z)-
trienic aldehyde 81 was synthesized by a Wittig reaction between aldehyde 78 with 
phosphonium salt 79, affording compound 80 that was hydrolyzed under acidic conditions to 
yield aldehyde 81. This aldehyde was reacted with phosphonium salt 85 yielding EPA (7) 
with the correct all Z-stereochemical geometry (Scheme 1.5).  
 
Scheme 1.5. Synthesis of EPA. 
Another example of the use of the Wittig reaction is the synthesis of leukotriene A4 methyl 
ester 91.119 The first step of this protocol was the reaction of the conjugated aldehyde 86 with 
the stabilized ylide 87 to afford mainly the cis-isomer 88 unexpectedly. The second Wittig 
reaction between the non-stabilized Wittig reagent 90 with aldehyde 89 gave the expected cis-
isomer 91. It is noted that in this synthetic approach, the epoxide and ester functional groups 
were not affected during the two Wittig reactions in this synthesis (Scheme 1.6).  
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Scheme 1.6. Synthesis of leukotriene A4 methyl ester. 
A combination of alkyne synthesis and the Wittig reaction was employed in the synthesis of 
bacillariolide I and II.120 The skipped triene-phosphonium iodide 96 was synthesized by the 
polyyne-semihydrogenation sequence. Coupling reaction of aldehyde 97a or 79b with Wittig 
reagent 96 afforded all-Z-tetraene 98. Hydrolysis of methyl acetal 98a or 98b by treatment 
with aqueous acetic acid, oxidation of hemiacetal with Jones reagent followed by removal of 
methoxymethyl group with acetic acid and concentrated hydrochloric acid afforded 
bacillariolide I (49) and bacillariolide II (50) (Scheme 1.7).  
 
 
Scheme 1.7. Synthesis of bacillariolide I and II. 
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1.9.3. Hemisynthseis of PUFAs 
Corey and co-workers have reported an efficient protocol for the synthesis of many 
eicosanoids using arachidonic acid as starting material.121-123 Iodolactonazition of arachidonic 
acid (12) afforded the iodolactone 99 which was treated with DBU to give the corresponding 
teteraene lactone 100, a precursor to 5-HPETE (28) and 5-HETE (29) (Scheme 1.8).124  
 
Scheme 1.8. Synthesis of 5-HPETE and 5-HETE. 
Juniperonic acid (110) was synthesized using the C-15 aldehyde 104 as the key intermediate 
that was formed via the iodolactonization of EPA (7). The Wittig reaction between aldehyde 
106 and triphenyl phosphonium iodide 107 afforded the acetal 108 that was deprotected to 
give the aldehyde 109. This aldehyde was oxidized by a Pinnick oxidation to afford 
juniperonic acid (110) (Scheme 1.9).125  
 
 
Scheme 1.9. Synthesis of juniperonic acid (110). 
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In 2004, Skattebøl and Hansen described the synthesis of two polyunsaturated pyrroles, 
mycalazol 5 (55) and mycalazal 2 (56) starting from EPA (7) (Scheme 1.10).126  
 
 
Scheme 1.10. Synthesis of mycalzol 5 and mycalazal 2. 
 
Another synthetic protocol was investigated by Anwar and Hansen again using EPA (7) as 
starting material for the synthesis of all-(Z)-5,7-dihydroxy-2-(4Z,7Z,10Z,13Z,16Z-
nonadecapentaenyl)chromone (57) (Scheme 1.11).127  
 
Scheme 1.11. Synthesis of polyunsaturated chromone metabolite. 
 
1. Introduction 
 
21 
 
1.9.4. Synthesis of PUFAs by cross coupling reactions 
The first total synthesis of resolvin E1 was reported by Serhan and Petasis and their co-
workers by using Pd-catalyzed cross coupling reactions of the building blocks 126 and 127 to 
form 128. This terminal alkyne was coupled with vinylic iodide 129 to afford the bis-
acetylenic precursor 130 that was reduced via stereocontrolled reduction to RvE1 (22) 
(Scheme 1.12).128  
 
 
Scheme 1.12. Synthesis of resolvin E1 (RvE1). 
 
Protectin D1/Neuroprotectin D1 (PD1/NPD1) was also synthesized via Pd-catalyzed coupling 
reaction of the two building blocks 131 and 132 to afford the acetylenic precursor 133 that 
was converted to PD1/NPD1 (24) via Z-selective semi-reduction and hydrolysis (Scheme 
1.13).129  
 
 
 
Scheme 1.13. Synthesis of protectin D1/neuroprotectin D1 (PD1/NPD1). 
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1.10. Syntheses of polyene system via iterative cross coupling (ICC) 
strategy 
An iterative synthetic approach is a powerful strategy that facilitate the synthesis of 
biopolymers, i.e. polypeptides, oligonucleotide and oligosaccharides.130-132 Recently, this 
strategy was employed in the synthesis of natural products.128,133,134 Burke and co-workers 
discovered that the trivalent N-methyliminodiacetic acid (MIDA) ligand (135) deactivates and 
blocks the boron center 134 by rehybridization to sp3configured 136.135 Consequently, the 
resulting MIDA boronates 136 are inactive towards transmetallation under anhydrous cross-
coupling conditions. They are tolerant of the Heck, Stille, Suzuki–Miyaura, and Sonogashira 
coupling protocols.135,136 
 
Scheme 1.14. Formation of sp3 hybridized boron. 
Burke and co-workers have employed the MIDA boronates in modular syntheses of some 
polyene natural products.133-136 The conjugated tetraene polyunsaturated fatty acid, β-
parinaric acid 142 was synthesized in three steps. The initial step is the Suzuki-Mayura 
reaction between the MIDA boronate 137 with the (E)-1-chloro-2-iodoethene 138 to form the 
di-functional dienyl chloride MIDA boronate 139 that was coupled with (E)-1-
butenylboronic acid to afford the all-trans trienyl boronate 140. The boron deprotection of 
140 was achieved under mild aqueous basic conditions, and subsequent cross-coupling with 
vinyl iodide 141 afforded β-parinaric acid (142).134 
 
Scheme 1.15. Synthesis of β-parinaric acid (142). 
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Burke and co-workers developed haloalkenyl MIDA boronates 143-146 in all possible 
stereomeric form that enable the synthesis of different polyene systems (Figure 1.20).137 
 
Figure1.22. Haloalkenyl Mida boronate 144-146. 
 
As an application for the utility of these MIDA boronates was the synthesis of the 
highly complex (E,E,E,Z,Z,E,E)-heptaene moiety found in vacidin A (147) (Scheme. 1.16).137 
 
 
Scheme 1.16. Synthesis of (E,E,E,Z,Z,E,E)-heptaene moiety. 
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1.11. Aim of Study 
 In this study, the aim was to use eicosapentaenoic acid (EPA) and eicosanoic acid 
(EA) as starting materials for the development of efficient synthesis of 
polyunsaturated pyrrole and polyunsaturated chromone derivatives. The newly 
synthesized analogs were subjected to biological testing. 
 In this thesis, the aim was also to synthesize bosseopentaenoic acid via an iterative 
cross coupling strategy using MIDA boronates.  
 Another study aimed at investigating the development of a reduction procedure for 
conjugated alkynes and non-activated alkynes to Z-alkenes by modification of the 
Zn(Cu/Ag) system initially investigated by Boland and co-workers. 
 The thesis also describes an attempted synthesis of α-parinaric acid.  
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2.   Results and Discussion 
2.1. Paper (I): Synthesis of mycalazol and mycalazal analogs with potent 
antiproliferating activities 
Due to the limited information on structure activity relationship of the pyrrole-based 
metabolites within the mycalazols and mycalazals class of metabolites,1 we aimed to 
synthesize some analogs with saturated and unsaturated C-20 alkyl chain at the position-5 of 
the pyrrole ring. We decided to use acids 7 and 152 as starting materials. The cytotoxic 
activity and structure activity relationship of the newly synthesized pyrroles were 
investigated. We also decided to prepare 2-acyl and 2-alkyl substituted thiophene derivatives 
with an unsaturated and saturated C-20 side chain to compare these compounds with the 
pyrrole-containing analogs.   
 
Figure 2.1. Structures of some polyunsaturated pyrrole-containing metabolites. 
The structurally related 2,5-disbstituted pyrroles isolated from the northeastern Atlantic 
sponge Mycale micracanthoxea, have been reported to be cytotoxic agents against five 
different cancer cell lines. These natural products contain either a saturated or an unsaturated 
carbon chain attached to the 5-position.2 
Abell and Nabb reported the synthesis and cytotoxicity of mycalazol 11 (153) and some 
related analogs.1 Recently Skattbøl and Hansen reported the synthesis of the polyunsaturated 
pyrrole metabolites mycalazol 5 (55) and mycalazal 2 (56) starting from eicosapentaenoic 
acid (EPA, 7).3 
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2.1.1. Synthesis 
Our strategy for the synthesis of the mycalazol 5 (55) and mycalazal 2 (56) analogs was based 
on a Stille coupling4 between the 5-(tri-n-butylstannyl)pyrrole-2-carboxaldehyde (157)5 and 
the corresponding acid chlorides of eicosapentaenoic acid (EPA, 7) and eicosanoic acid (EA, 
152). The synthesis of stannyl compound 157 started with the preparation of the dimer 155 
from commercial available pyrrole-2-carboxaldehyde (154) and 40% aqueous dimethyl amine 
using a literature procedure6 to afford compound 155 in quantitative yield. Lithiation of 
compound 155 was accomplished with 2.3 equivalents of n-butyllithium, and then reaction 
with tri-n-butylstannyl chloride provided compound 156. Aqueous hydrolysis of compound 
156 with sodium acetate afforded stannyl compound 157 in 57% overall yield from 2-pyrrole-
carboxyaldehyde (154) (Scheme 2.1). 
 
Scheme 2.1. Synthesis of 5-(tri-n-butylstannyl)pyrrole-2-carboxaldehyde 157. 
 
The synthesis of the acid chlorides 158 and 159 were carried out by treating EA (152) and 
EPA (7) with excess oxalyl chloride in dichloromethane. This afforded the acid chlorides 158 
and 159 in quantitative yields. Subsequently, a Stille coupling of the acid chlorides with the 
stannylpyrrole carboxaldehyde 157 afforded the analogs 160 and 161 in 76% and 71% yield, 
respectively. The reduction of the formyl group was carried out selectively in the presence of 
the carbonyl group and the double bonds in the unsaturated chain (at postion-5) using freshly 
prepared Zn(BH4)27 in THF at 0-25 oC. The analogs 162 and 163 were obtained in 88% and 
93% yields, respectively (Scheme 2.2). 
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Scheme 2.2. Synthesis of analogs 160-163. 
 
The synthesis of 2-acyl thiophene analog 165 was carried out using a Stille coupling between 
acid chloride 159 and commercially available 2-(tri-n-butylstannyl)pyrrole (164) to afford 
165 in 84% yield. Reduction of the carbonyl group using Pd/C and H2 in the presence of 
catalytic amounts of sulphuric acid provided compound 166 in 87% yield (Scheme 2.3).  
 
 
Scheme 2.3. Synthesis of thiophene analogs 165 and 166. 
 
2.1.2. Biological studies 
Mycalazol 5 (55) and mycalazal 2 (56), the synthesized pyrrole analogs 160-163 and the 
thiophene analogs 165 and 166 were tested against four human cancer cell lines; two types of 
ovarian cancer cell lines (SKOV and OVCAR) and two types of melanoma cancer cell lines 
(WM35 and WM239). These were compared with the original lines (VERO). All the 
compounds exhibited potent cytotoxic activity with IC50-values in the nanomolar range, 
except compound 166, which was inactive. 
 
Mycalazol 5 (55) and mycalazal 2 (56) were more active than the prepared analogs. 
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Mycalazol 5 (55) was slightly more cytotoxic than mycalazal 2 (56). This result was in 
agreement with the previous report by Salvá and co-workers.2 The two pyrrole-containing 
analogs 160 and 161 were the most active compounds among the other prepared analogs. It 
was observed that compound 161 (IC50-values 11.3-22.9 nM) showed higher activity than 
compound 160 (IC50-values 15.9-31.1 nM). It was observed that the 2-acyl substituted 
thiophene 165 showed decrease cytotoxicity compared to the other analogs. The 2-alkyl 
thiophene 166 was inactive towards all four cancer cell lines and the VERO cells. All the 
other analogs have potent cytotoxic effect on the original cells (VERO). Hence, no selectivity 
was observed. The biological results are summarized are in Table 2.1. 
 
 
Compounds SKOVa OVCARa WM35a WM239a VEROa 
55 14.9 (±2.1) 9.4 (±1.8) 2.9 (±0.9) 2.1 (±0.9) 2.1 (±0.9) 
56 23.3 (±3.0) 18.0 (±2.1) 4.1 (±1.0) 4.3 (±0.8) 4.3 (±0.8) 
160 31.1 (±2.3) 24.1 (±1.5) 13.0 (±1.3) 15.9 (±1.9) 15.9 (±1.9) 
161 22.9 (±1.9) 21.7 (±2.8) 11.3 (±1.9) 12.1 (±2.1) 12.1 (±2.1) 
162 38.1 (±2.1) 38.5 (±2.2) 36.4 (±2.1) 27.7 (±2.2) 27.7 (±2.2) 
163 34.3 (±3.3) 32.7 (±4.1) 24.1 (±2.6) 20.5 (±2.9) 20.5 (±2.9) 
165 49.1 (±2.1) 58.7 (±3.3) 45.5 (±3.3) 58.0 (±2.9) 58.0 (±2.9) 
166 >100 >100 >100 >100 >100 
 
aValues (nM) are means of three experiments in each cell assay. Standard deviation is given in parentheses 
Table 2.1. 
The results of this study have been described in Paper I and the experimental procedure and 
spectroscopic data are attached in the appendix. 
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2.2. Paper (II): Polyunsaturated fatty acid-derived chromones exhibiting 
potent antioxidant activity  
The aim of this study was to develop efficient synthesis of some analogs of polyunsaturated 
chromone metabolite 57 and to investigate their susceptibility to oxidation.  
Several diseases are associated with cellular oxidation processes. These oxidation processes 
may be retarded in the presence of antioxidants. Oxidative DNA damage is associated with 
cancer,8,9 aging and neurodegenerative diseases such as Alzheimer’s and Parkinson’s10-14 and 
cardiovascular diseases such as arteriosclerosis.15 Therefore, prevention of oxidative stress 
caused by reactive oxygen/nitrogen species (ROS/RNS) has important implications in 
prevention and treatment of such diseases. Phenolic compounds, such as quercetin (167) are 
recognized for their antioxidant activity due to their ability to scavenge free radical. These 
compounds sacrificially reduce the ROS/RNS preventing damage to biomolecules or 
formation of more ROS.16 However, limited bioavailability of quercetin (167) has been 
reported.17 It has been reported that EPA (7) showed potent antioxidant effect by reducing the 
formation of ROS.18 From this practical point of view and in continuation of the previous 
work on the synthesis and biological evaluation of polyunsaturated natural products,19 we 
became interested in using the chromone-based metabolite 57 as a lead compound for 
preparing new lipophilic antioxidants. This natural product is characterized by possessing the 
same (5,7-dihydroxy chromone) moiety as that present in quercetin (167). Compound 57 also 
has an unsaturated chain containing five methylene-interrupted cis-double bonds as those 
present in EPA (7). The natural product 57 was isolated from different algae.20 The total 
synthesis of 57 was reported using EPA (7) as starting material.21 To the best of our 
knowledge, no biological data for this polyunsaturated natural product has been reported. 
 
Figure 2.2. The structure of quercetin (167) and the natural product 57. 
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2.2.1.  Synthesis  
Compound 57 was prepared as previously reported.21 The hydroxyl group in compound 57 
was alkylated to provide compound 168 in 85% yield. This compound was hydrolyzed under 
mild basic condition to afford acid 169 in 88% yield. Methylation of the hydroxyl groups in 
compound 57 provided compound 170. Reduction of compound 57 using Pd/C (5 mol%) gave 
the saturated chain derivative 171 in 98% yield. Subsequently, this compound was methylated 
to afford compound 172 in 89% yield (Scheme 2.4). 
 
Scheme 2.4. Synthesis of chromone analogs. 
2.2.2.  Synthesis of 3-(1-alkynyl) chromone derivatives 
In this study, we developed new derivatives of the natural product 57 with polyunsaturated 
and saturated side chains attached to the position-3 in the chromone moiety. These analogs 
contain a triple bond in conjugation with the chromone ring. 
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Figure 2.3. New chromone derivatives based on the Sonogashira reaction. 
We started our synthesis of the chromone derivatives by preparing the alkynes 12221,22 and 
180 by the Corey-Fuchs reaction23 on the aldehydes derived from EPA (7) and EA (152) 
(Scheme 2.5). 
 
Scheme 2.5. Synthesis of the alkynes 122 and 180. 
 
We prepared two types of iodochromones using a literature procedure.24,25 The synthesis of 
compound 184a or 184b started by the formation of the protected hydroxyl compounds 182a 
or 182b. These compounds were treated with dimethylformamide-dimethylacetal to afford 
enaminone 183a or 183b, respectively. The enaminone 183a was reacted with iodine in 
dichloromethane in the presence of pyridine, which gave 184a in 42% overall yield from 
181a, while the enaminone 183b was reacted with iodine in methanol to afford compound 
184b in 39% overall yield from 181b (Scheme 2.6). 
 
Scheme 2.6. Synthesis of iodochromones 184a,b. 
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Alkyne 122 or 180 was reacted with iodochromone 184a in a Sonogashira reaction.26 The 
resulting products were reacted with p-toluenesulphonic acid (10 mol%) to afford chromone 
derivatives 185a and 186a in 82% and 80% yields, respectively. The hydroxyl groups in 185a 
and 186a were alkylated using MeI in acetone in the presence of K2CO3 to afford the analogs 
185b and 186b in 80% and 87% yields, respectively.  
 
 
Scheme 2.7. Synthesis of the chromone analogs 185a,b and 186a,b. 
 
Alkyne 122 or 180 was then reacted with iodochromone 184b. The resulting products were 
refluxed in MeOH/CH3Cl in the presence of concentrated HCl to remove the methoxymethyl 
groups to afford compounds 187a and 188a in 80% and 83% yields, respectively. After the 
alkylation of 187a and 188a, compounds 187b and 188b were obtained in 83% and 93% 
yields, respectively (Scheme 2.8).  
 
 
Scheme 2.8. Synthesis of chromone analogs 187a,b and 188a,b. 
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2.2.3. Biological studies 
Compounds 57, 167 and 169-172 were evaluated in the cellular lipid peroxidation antioxidant 
activity (CLPAA) assay using HepG2 cells.27 The most potent compounds were quercetin 
(167) and the natural product 57 with IC50= 10±3 and 14±9 μM, respectively. The analog 169 
showed modest activity. Neither the dimethylated compounds 170 and 172, nor compound 
171 showed any inhibitory activity. From this point of view, it is observed that the 
compounds that contain free hydroxyl group with the polyunsaturated side chain have the 
potential to oxidize and prevent formation of ROS (Table 2.2). 
Compound IC50a (μM) IC50b (μM) ClogPd 
57 14±9 160±25 8.4 
167 10±3 71±39 1.5 
169 29±3 342±122 8.9 
170 > 1000 n.d.c n.d.c 
171 > 1000 n.d.c n.d.c 
172 > 1000 n.d.c n.d.c 
 
a:The IC50-value was determined based on three experiments in the CLPAA assay 
b: The IC50-value was determined based on three experiments in the CAA assay 
c: not determined 
d: ClogP determined from the SciFinder Scholar database 
 
Table 2.2. 
The compounds 185a,b, 186a,b, 187a,b and 188a,b will also be subjected to a lipid 
peroxidation antioxidants and cytotoxic assay. The results from biological testing will be 
reported in due course (Figure 2.4.).  
 
Figure 2.4. 
 
The results of this study have been described in Paper II, and the experimental procedure and 
spectroscopic data are attached in the appendix. 
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2.3. Paper (III): First total synthesis of methyl (5Z,8Z,10E,12E,14Z)-
eicosapentaenoate 
The aim of this study was to develop an efficient and stereoselective synthesis for 
bosseopentaenoic acid (20) or its methyl ester 189. 
 
Figure 2.5. Bosseopentaenoic acid (20) and its methyl ester 189. 
 
Marine organisms have been shown to be a source for PUFAs and their related metabolites.28 
Many of these metabolites have interesting biological activity.29 Bosseopentaenoic acid (20) 
was isolated from the red algae Bossiella orbigniana by Burgess and co-workers in 1991.30 
Subsequently, the methyl ester 189 was isolated by Gerwick and co-workers in 1993 from the 
red marine alga Lithothamnion corallioides, collected from the south coast of Norway.31 In 
1995, Jacobs and co-workers isolated the same ester along with other conjugated PUFAs from 
the green alga Anadyomene stellata.32 This PUFA contains four conjugated double bonds with 
the (Z,E,E,Z)-moiety, along with one methylene interrupted Z-double bond; five double bonds 
in total.  
The biosynthetic pathway for bosseopentaenoic acid (20) from arachidonic acid (AA, 12) was 
proposed by Burgess and co-workers (Scheme 2.9).30 
 
Scheme 2.9. Proposed biosynthetic pathway of bosseopentaenoic acid (20). 
We decided to synthesize this fatty acid via consecutive palladium catalyzed cross coupling 
reactions. Our retrosynthetic analysis leads to the two building blocks 191 and 192. 
Phytochemistry 1993, 34, 1029–1033.  Lipids 1995, 30, 583–589.  
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Compound 191b (X= Cl) can be obtained from compound 193 which can be obtained from 
the MIDA boronate 198 developed by Burke and co-workers (Scheme 2.10).33 
 
Scheme 2.10. Retrosynthetic analysis of bosseopentaenoicacid (20) and its methyl ester 189. 
Our initial strategy for obtaining the key intermediate 191a (X= I) was a Wittig reaction 
between 2-octynal (199) and the stabilized ylide 200 to afford the adduct (E:Z, 98:2) 201 in 
83% yield. This was reduced to the corresponding alcohol 202 in 82% yield using 
diisobutylaluminium hydride, and a subsequent oxidation provided 203. Aldehyde 203 was 
used in a Takai reaction34 to afford compound 191a in 69% yield as a mixture of two isomers 
(E,E:E,Z, 75:25), as determined by1H NMR (Scheme 2.11). 
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Scheme 2.11. Synthetic route for compound 191a. 
 
Figure 2.5. 1H NMR for compound 191a. 
Since we could not obtain compound 191a as a single isomer from the aforementioned 
described syntheses, we decided to prepare compound 191b using the recently synthetic 
iterative protocol developed by Burke and co-workers.33,35,36 The synthesis of compound 191b 
(X=Cl) started by the formation of compound 193 via a Sonogashira reaction26 of MIDA 
boronate 198 and alkyne 197. The MIDA boronate 193 was obtained in 82% yield. This 
MIDA boronate is a precursor of its boronic acid after basic hydrolysis with 1N NaOH as 
previously reported.33,35,36 From this point of view, we decided to react the Mida boronate 193 
with trans-1,2-dichloroethene (194) in a Suzuki-Miyaura reaction37 affording compound 191b 
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in 70% yield. In contrast with the previous strategy, the produced compound 191b was 
obtained as the E,E-isomer only (Scheme 2.12). 
 
Scheme 2.12. Synthetic route for compound 191b. 
 
 
Figure 2.7. 1H NMR for compound 191b. 
Alkyne 192 was synthesized according to a literature procedure.38 The commercially available 
propargyl bromide 195 was reacted with alkyne 196 to obtain skipped alkyne 204 in 80% 
yield, followed by a stereoselective reduction of the internal triple bond using the Lindlar 
catalyst.39 This gave compound 205 in 71% yield. Deprotection of the silyl group in 
compound 205 was carried out by treatment with potassium fluoride in methanol to afford 
compound 192 in 90% yield. This terminal alkyne was then reacted with trans-1,2-
dichloroethene (194) in a Sonogashira reaction to afford compound 206 in 51% yield. 
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Hydrolysis of the MIDA boronate 193 under mild aqueous basic condition using 1 N NaOH 
to afford its boronic acid that was reacted with compound 206 via a Suzuki-Miyaura reaction 
to provide compound 190 in 47% yield. Due to the low yield of compound 190, we decided to 
synthesize this compound by reacting compound 192 with compound 191b via a Sonogashira 
reaction to afford diyne 190 in 64% yield. The diyne 190 was recovered when subjected to the 
reduction using Boland reduction procedure.40 Then we tried to modify the Boland procedure 
by adding TMSCl to the reaction. This provided the methyl ester of bosseopentaenoic acid 
189 in 88% (Scheme 2.13). This modification of Boland procedure was investigated in an 
extended study (Chapter 2.4).  
 
Scheme 2.13. Synthesis of bosseopentaenoic acid methyl ester 189. 
In conclusion, methyl (5Z,8Z,10E,12E,14Z)-eicosapentaenoate (189) was synthesized in 16% 
overall yield over seven steps. Our attempts to obtain acid 20 from ester 189 by hydrolysis 
under different basic conditions failed due to the sensitivity of compound 189 that either 
polymerized or decomposed under basic condition. 
The results of this study have been summarized in Paper III, and the experimental procedure 
and spectroscopic data are attached in the appendix. 
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2.4. Paper (IV): Z-Stereoselective semi-reduction of alkynes: Modification 
of the Boland reduction protocol 
The semi-reduction of alkynes to cis-alkenes is an important reaction in organic synthesis and 
in total synthesis of natural products.41 The most popular catalyst used for Z-stereoselective 
semi-reduction of alkynes to Z-alkenes is the Lindlar catalyst.39 However, this catalyst has 
some drawbacks, such as reproducibility and over-reduction to alkanes. Most serious is the 
problem with obtaining high Z-selectivity, especially in case of conjugated alkynes that lead 
to mixtures of E- and Z-isomers.42 We have reported the first total synthesis of methyl 
(5Z,8Z,10E,12E,14Z)-eicosapentaenoate (189).43 During this project we conducted some 
stereoselective reductions of alkynes to cis-alkenes using the Lindlar catalyst, but this 
catalyst failed to provide high cis-selectivity in conjugated systems. Hence, we needed to 
develop an improved protocol. For the reduction of the two triple bonds in compound 190 to 
obtain the natural product 189 (Scheme 2.14) we tried the Zn(Cu/Ag) system developed by 
Boland and coworkers.40 However, only a 5% isolated yield was obtained after 24 hours at 
room temperature.  
When we tried the Zn(Cu/Ag) system in presence of trimethylsilyl chloride, the reduction of 
190 was highly accelerated. The methyl ester of bosseopentaenoic acid 189 was obtained 
with high Z-selectivity in excellent yield (Table 2.3). 
 
Scheme 2.14. Semi-reduction of compound 190. 
Amount of TMSCl Reaction time yield 
without 24 h 5% 
1 eq.  8 h 30% 
5 eq. 4 h 82% 
10 eq. 1 h 88% 
 
Table 2.3. Amount of TMSCl added. 
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We have carried out this procedure with a variety of conjugated alkynes (Table 2.4). 
Alkyne Product 
Time 
(min) 
Diasteromeric
ratioa Yield (%)
b 
 
 
 
 
 
60 50:1 88 
 
 
 
 
30 19:1 90 
 
 
 
 
30 25:1 92 
 
 
 
 
90 50:1 82 
 
 
 
 
90 19:1 87 
 
 
 
 
90 19:1 86 
 
 
 
 
90 16:1 89 
 
 
 
 
60 50:1 86 
 
a:The diastereomeric ratios of the alkenes were determined by HPLC analysis. Two experiments were performed. The 
ratio is given of the diasteromer depicted compared to the sum of all other diasteromers formed. The structures of the 
minor diasteromers were not determined. b:The yields are of the Z-diasteromer depicted and determined after 
purification by chromatography and are the average of two experiments. 
Table 2.4. Reduction of E-conjugated alkynes. 
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It is noteworthy that the Zn(Cu/Ag) system does not reduce non-activated alkynes such as 
diphenylacetylene (221). However, we aimed to investigate the effect of the additives on the 
Zn(Cu/Ag) system for this type of reduction (Table 2.5). 
 
Scheme 2.15. Reduction of diphenylacetylene (221) as model substrate. 
Entry  Additives 221: 222: 223: 224c Time (h) Isolated yield %e 
1  without - 36 h - 
2  TMSCla 88.0: 0 : 12.0: 0 24 h n.d.d 
3  HClb 49.2: 0 : 1.6 : 49.2  24 h n.d.d 
4  TMSCl /ZnCl2 98.1 : 0 : 1.9 : 0 24 h n.d.d 
5  TMSCl /CuI 90.8: 0 : 9.2 : 0  24 h n.d.d 
6  TMSCl 79.2 : 0: 20.8: 0 36 h 28 
7  TMSCl / HSiEt3 35.0: 0 : 65.0 : 0  24 h 70 
8  HSiEt3 - 24 h - 
 
a:TMSCl (10 eq);  b:1N HCl; c:Determined by GLC; d:not determined; e:Purified on silica gel (hexane).   
Table 2.5. The effect of different additives. 
 
We observed that the addition of TMSCl did not produce cis-stilbene 223 to a large extent. 
The reduction of alkyne 221 using the Zn(Cu/Ag) system was most efficient after adding both 
triethylsilane44 and trimethylsilyl chloride (entry 7). The resulting product was only the cis-
isomer 223 without any detection of the trans-isomer by 1H NMR and GLC analyses. 
Moreover, adding triethylsilane alone (entry 8) yielded no conversion of 1,2-
diphenylacetylene (221). Subsequently, we tested this newly investigated procedure on a 
variety of non-activated alkynes (Table 2.6).   
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Alkyne Product Time (h) Diasteromeric ratioa Yield (%)b 
 
 
 
 
24 >98 70 
 
 
 
 
 
 
24 >98 70 
 
 
 
 
 
18 
 
 
>98 
 
 
72 
 
 
 
 
+  
 
 
15 
 
>98 
 
54 
 
 
 
 
30 
  
15 >98 70 
 
 
 
 
15 >98 60 
a:The diastereomeric ratios of the alkenes were determined by GLC analysis. Two experiments were performed. The 
ratio is given of theZ-diasteromer. The structures of the minor diasteromers were not determined; b:The yields are of 
the Z-diasteromer determined after purification by chromatography and are the average of two experiments. 
Table 2.6. Reduction of 1,2-diaryl alkynes and alkynylthiophene derivatives. 
 
The use of HSiEt3 as an additive with the Zn(Cu/Ag)/TMSCl leads to an efficient 
stereoselective semi-reduction of non-activated alkynes to Z-alkenes in good yields and high 
selectivity. This study adds a new value to the Boland reduction, since we have improved this 
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system to be efficient for several non-activated alkynes. A range of functional groups were 
tolerated in this procedure, such as chloro and acetyl. These functional groups were not 
affected under the reaction condition. However, the nitro group in compound 228 was 
reduced to amine under this reaction condition to afford (Z)-4-styrylaniline (229) and 4-
(phenylethynyl)aniline (230) in 54% and 30% yields, respectively. The reduction of alkynyl 
thiophene to Z-alkenyl thiophene is not easy and isomeric mixtures of alkenes have often been 
reported.45 The improved procedure was efficient for highly Z-selective semi-reduction of 
alkynyl thiophenes 231 and 233 affording Z-alkenyl thiophenes 232 and 234 in 70% and 60% 
yields, respectively (Table 2.6).  
In conclusion, the Boland reduction procedure has been accelerated and improved by the 
addition of TMSCl. In this study, the synthesis of Z-alkenes could be achieved by 
hydrosilylation-protodesilylation process.46 The mechanism of this reaction will be 
investigated in due course. The new modified reduction protocol facilitates the synthesis of 
sensitive or highly unsaturated polyene compounds, such as PUFAs or natural products that 
possess a polyene framework.  
 
The results of this study have been described in Paper IV and the experimental procedure and 
spectroscopic data were attached in the appendix. 
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2.5. Synthetic studies towards α-parinaric acid 
After the synthesis of the methyl ester of bosseopentaenoic acid 18943 and also after the 
development of the efficient procedure for stereoselective semi-reduction of alkynes to their 
corresponding cis-alkenes using the Zn(Cu/Ag)/TMSCl system,47 we became interested in the 
synthesis of another polyene natural product. We therefore aimed to develop an efficient 
synthesis of α-parinaric acid (19), a conjugated tetraenoic fatty acid which possess the 
(Z,E,E,Z) moiety (Figure 2.8). 
 
Figure 2.8. The chemical structure of α-Parinaric acid (19). 
α-Parinaric acid (19) was isolated by Tsujimoto and Koyanagi in 1933.48 This natural product 
exhibit potent cytotoxic acidity49 by sensitizing the tumor cells to lipid peroxidation, the 
process where free radicals react with electrons from cell membrane lipids, resulting in cell 
damage. It was reported that a mixture of three isomers of parinaric acids were prepared by 
bromination of α-linolenic acid and subsequent dehydrobromination.50 
Due to the unique structure of α-parinaric acid (19) and its interesting bioactivity, we decided 
to synthesize this natural product by total synthesis. 
Based on our published synthesis of methyl (5Z,7Z,9E,11E,13Z)-eicosapentaenoate (189),43 
the synthesis of α-parinaric acid (19) also depends on several palladium catalyzed cross 
coupling reactions. Our retrosynthetic analysis leads to compound 198 as the key starting 
material (Scheme 2.16).35 
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Scheme 2.16. Retrosynthetic analysis of α-parinaric acid (19). 
Our synthetic strategy started with a Sonogashira coupling between 1-butyne (238) and 
MIDA boronate 198 to afford adduct 236 in 69% yield (Scheme 2.17). 
 
Scheme 2.17. 
The synthesis of compound 237 started with the synthesis of 241 from the commercially 
available alcohol 240 via an alkyne zipper reaction, transferring the internal alkyne to the 
terminal position, using literature procedure to afford alcohol 241.51 Oxidation of the alcohol 
241 using the Dess-Martin periodinane reagent52 afforded aldehyde 242 in 94% yield, which 
was then reacted with ethylene glycol in the presence of a catalytic amount of p-
toluenesulphonic acid to give the corresponding acetal 239 in 87% yield. The Sonogashira 
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coupling between compound 239 and 194 afforded compound 237 in 64% yield (Scheme 
2.18). 
Scheme 2.18. 
By the reaction of compound 237 with MIDA boronate 236 via a Suzuki-Miyauara cross 
coupling reaction, we obtained compound 235 in 32% yield (Scheme 2.19).  
Scheme 2.19. 
The produced compound 235 can be a precursor for the synthesis of Į-parinaric acid (19) by 
stereocontrolled reduction using the Zn(Cu/Ag)/TMSCl system.47 Then deprotection of the 
acetal group to the aldehyde followed by oxidation using Pinnick oxidation method,53 should 
yield the acid 19. 
Scheme 2.20. 
The experimental procedure and spectroscopic data of this study are attached in the appendix. 
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3.  Summary 
An efficient synthesis of new polyunsaturated pyrroles has been reported. The new analogs 
were synthesized via a Stille coupling without using protecting groups for either the NH or 
the formyl group. The natural products mycalazol 5 (55) and mycalazal 2 (56) and the newly 
synthesized analogs were subjected to biological testing against different cancer cell lines. 
Mycalazol 5 (55) and mycalazal 2 (56) were the most active compounds; the two analogs 
possessing unsaturated alkyl chains showed slightly decreased cytotoxity than the natural 
products.  Changing the pyrrole ring with a thiophene ring led to a further decrease in the 
cytotoxic activity. 
An efficient synthesis of analogs of the polyunsaturated chromone 57 was reported. These 
new analogs exhibited potent antioxidant activity. It was observed that the compounds with 
free hydroxyl groups and polyunsaturated side chains exhibited antioxidative properties better 
than the other analogs. 
The methyl ester of bosseopentaenoic acid (189) was synthesized via iterative palladium-
catalyzed cross coupling using MIDA boronates in seven steps and in 16% overall yield. 
The development of a highly Z-stereoselective semi-reduction method of alkynes to Z-alkenes 
was achieved by modification of the Boland reduction protocol. The diasteromeric ratios of 
the produced compounds ranged between 50:1 to 16:1. Also, this protocol was modified to the 
reduction of non-activated alkynes affording Z-stilbenes. 
We have described synthetic studies towards α-parinaric acid (19) via iterative palladium-
catalyzed cross coupling reactions. In this protocol, the construction of the conjugated diyne 
235 has been achieved. This diyne is a precursor for the α-parinaric acid.  
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Appendix 
Experimental section 
General information 
All reagents and solvents were used as purchased without further purification. Melting points 
were determined in open capillary tubes and are uncorrected. Analytical TLC was performed 
on silica gel 60 F254 Aluminium sheets (Merck). Flash column chromatography was 
performed on silica gel 60 (40-60 m, Fluka). NMR spectra were recorded on a 
BrukerAvance DPX spectrometer at 300 or at 400 MHz for 1H NMR, 75 or 101 MHz for 13C 
NMR respectively. Coupling constants (J) are reported in hertz, and chemical shifts are 
reported in ppm () relative to CDCl3 (7.24 ppm for 1H and 77.40 ppm for 13C), DMSO-d6
(2.49 ppm for 1H and 39.5 ppm for 13C) and pyridine-d5 (8.71, 7.55, 7.19 for 1H and 149.9, 
135.5, 13.5 for 13C). High resolution mass spectra were performed with VG Prospec mass 
spectrometer. 
Procedures and spectral data 
Eicosan-1-ol (178). 
To a stirred solution of eicosanoic acid (152) (6.0 g, 16.78 mmol) in Et2O (100 ml), fresh 
LiAlH4 (0.869 g, 23.49 mmol) was added portionwise over 10 minutes at 0 °C. The mixture 
was stirred at 0 °C for 30 minute. Water (1 ml) was then added at 0 °C, followed by addition 
of 15% aq. NaOH (3.5 ml) and then water (1 ml) once more. The reaction mixture was dried 
over MgSO4, filtered. The solvent was evaporated under reduced pressure to afford compound 
178 in quantitative yield as white solid (5.50 g, 96%). 1H NMR (300 MHz, CDCl3):  3.62 (t, 
J = 6.6 Hz, 2H), 1.59-1.50 (m, 2H), 1.31-1.24 (m, 34H), 0.86 (t, J = 6.6 Hz, 3H).13C NMR (75 
MHz, CDCl3):  63.51, 33.23, 32.33, 30.09 (8 x CH2), 30.06 (2 x CH2), 30.01, 30.00, 29.83, 
29.76, 26.14, 23.09, 14.51. HRMS Calcd. for C20H42O [M]+ 298.3236, found 298.3231. 
Eicosanal (179). 
Eicosanol (178) (5 g, 16.8 mmol) and silica gel (10 g, 166 mmol) were dissolved in CH2Cl2
(75 ml), followed by addition of pyridinium chlorochromate (5.4 g, 25.2 mmol). The reaction 
mixture was allowed to stir for 3 h at room temperature and then the mixture was filtered 
through a short plug of silica gel. The solvent was evaporated under reduced pressure to 
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afford a residue that was purified by column chromatography (silica gel, hexane/EtOAc, 9:1) 
to yield compound 179 as white solid (4.72 g, 95%). 1H NMR (300 MHz, CDCl3):  9.74 (t, J
= 1.8 Hz, 1H), 2.39 (td, J = 7.4, 1.9 Hz, 2H), 1.65-1.55 (m, 2H), 1.32-1.23 (m, 32H), 0.85 (t, J
= 6.6 Hz, 3H).13C NMR (75 MHz, CDCl3):  203.28, 44.31, 32.32, 30.09 (8 x CH2), 30.05, 
30.02, 29.97, 29.82, 29.75, 29.56, 23.08, 22.49, 14.50. HRMS Calcd. for C20H40O [M]+
296.3079, found 296.3074. 
Heneicos-1-yne (180). 
To a stirred mixture of zinc (1.2 g, 21.43 mmol) and triphenylphosphine (4.80 g, 18.32 
mmol), carbon tetrabromide (6.10 g, 18.37 mmol) was stirred in CH2Cl2 (100 ml) for 40 h at 
room temperature. Aldehyde 179 (2.16 g, 7.29 mmol) in CH2Cl2 (20 ml) was added and 
stirred for 1 h at room temperature. The mixture was filtered through a short plug of silica gel. 
The filtrate was evaporated to yield pure dibromide as white solid (3.04 g, 92%). 1H NMR 
(300 MHz, CDCl3):  6.36 (t, J = 7.2 Hz, 1H), 2.07 (q, J = 7.3 Hz, 2H), 1.24 (s, 34H), 0.86 (t, 
J = 6.6 Hz, 3H). 13C NMR (75 MHz, CDCl3):  139.29, 88. 84, 33.42, 32.34, 30.11(8 x CH2), 
30.08, 30.03, 29.93, 29.78, 29.75, 29.46, 28.21, 23.11, 14.53. To a solution of the dibromide 
(2 g, 4.54 mmol) in dry THF (60 ml), n-BuLi (3.47 ml, 5.56 mmol, 1.6 M in hexane) was 
added at -78 °C. The reaction mixture was allowed to stir at -78 oC for 1 h and then the 
mixture was allowed to warm at room temperature, followed by addition of water (50 ml). 
The mixture was extracted with hexane (2x50 ml). The combined organic layers was washed 
with brine (30 ml), dried (MgSO4) and filtered. The solvent was evaporated under reduced 
pressure to afford a residue that was purified by column chromatography (silica gel, hexane) 
to yield alkyne 180 as white solid (1.18, 91%). 1H NMR (300 MHz, CDCl3):  2.16 (td, J = 
7.0, 2.6 Hz, 2H), 1.91 (t, J = 2.6 Hz, 1H), 1.55-1.46 (m, 2H), 1.39-1.24 (m, 30H), 0.86 (t, J = 
6.6, 3H). 13C NMR (75 MHz, CDCl3):  85.21, 68.39, 32.32, 30.09 (8 x CH2), 30.06, 30.01, 
29.91, 29.76, 29.51, 29.17, 28.90, 23.09, 18.80, 14.51. HRMS Calcd. for C21H40 [M]+
292.3130, found 292.3130. 
1-(2-Hydroxy-4,6-bis(methoxymethoxy)phenyl)ethanone (182b). 
To a solution of 1-(2,4,6-trihydroxyphenyl) ethanone (181b) (1 g, 5.4 mmol) in acetone (10 
ml), anhydrous K2CO3 (5.2 g, 40 mmol) was added, followed by addition of methoxy methyl 
bromide (1.68 g,  1.68 mmol). The mixture was heated at reflux for 12 h, then cooled to room 
temperature, filtered and evaporated under reduced pressure. The residue was purified by 
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column chromatography (silica, hexane/EtOAc, 7:3) to yield compound 182b as white solid 
(0.76 g, 54%). 1H NMR (300 MHz, CDCl3):  13.69 (s, 1H), 6.25 (d, J = 2.3 Hz, 1H), 6.22 (d, 
J = 2.3 Hz, 1H), 5.23 (s, 2H), 5.15 (s, 2H), 3.50 (s, 3H), 3.45 (s, 3H), 2.63 (s, 3H).13C NMR 
(75 MHz, CDCl3):  203.59, 167.22, 163.84, 160.74, 107.34, 97.55,  94.87,  94.41 (2 x CH), 
57.10, 56.85, 33.41. 
3-Iodo-5,7-bis(methoxymethoxy)-4H-chromen-4-one (184b). 
Ketone 182b (0.181 g, 0.70 mmol) and DMFDMA (0.1 ml, 0.76 mmol) was heated at 95 oC 
for 1.5 h. The reaction was then cooled at room temperature. The excess of DMFDMA was 
evaporated under reduced pressure using rotavapor. The residue was purified by column 
chromatography (silica gel, hexane/EtOAc, 1:1) to afford enaminone 183b as yellow solid 
(0.192 g, 87%). To a stirred solution of 183b (225 mg, 0.76 mmol) in MeOH (20 ml), iodine 
(260 mg, 1.02 mmol) was added as solid to the solution. The reaction mixture was allowed to 
stir overnight at room temperature. A solution of sat. aq. sodium thiosulfate (30 ml) was 
added and the mixture was extracted by CHCl3 (3x50 ml). The organic solution was dried 
(MgSO4), filtered and evaporated under reduced pressure. The resulting crude product was 
purified by column chromatography (silica gel, hexane/EtOAc, 1:1) to afford compound 184b
as white solid (0.251 g, 84%). m.p. 138-140 oC.1H NMR (300 MHz, CDCl3):  8.06 (s, 1H), 
6.72 (d, J = 2.3 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 5.27 (s, 2H), 5.19 (s, 2H), 3.51 (s, 3H), 3.46 
(s, 3H). 13C NMR (75 MHz, CDCl3):  171.63, 161.90, 159.06, 158.52, 156.03, 109.11, 
102.40, 97.11, 95.81, 94.75, 89.83, 57.11, 56.98. 
3-((6Z,9Z,12Z,15Z,18Z)-Henicosa-6,9,12,15,18-pentaen-1-yn-1-yl)-7-hydroxy-4H-
chromen-4-one (185a). 
To a stirred solution of compound 184a (1.116 g, 3 mmol), CuI (114 mg, 0.6 mmol) and 
Pd(Ph3P)2Cl2 (63 mg, 0.09 mmol) in THF (9 ml), triethylamine (1.25 ml, 9.0 mmol) was 
added, followed by addition of alkyne 122 (1.27 g, 4.5 mmol). The reaction mixture was 
allowed to stir at room temperature for 2 h. The mixture was then diluted with EtOAc (20 ml) 
and washed with sat. aq. NH4Cl. The organic solution was dried over MgSO4, filtered and 
evaporated under reduced pressure. The resulting crude product was dissolved in MeOH/THF 
(1:1, 180 ml), followed by addition of p-toluenesulfonic acid monohydrate (95 mg, 0.5 
mmol). This mixture was stirred at 60 °C for 1 h and then allowed to cool to room 
temperature. Et3N (0.69 ml, 5.0 mmol) was added. The mixture was evaporated to afford a 
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residue that was purified by column chromatography (silica gel, hexane/EtOAc, 7:3) to give 
compound 185a as brown oil (1.08 g, 82%). 1H NMR (300 MHz, CDCl3):  9.20 (br s, 1H), 
8.11 (d, J = 8.8 Hz, 1H), 8.03 (s, 1H), 7.24 (s, 1H), 7.09 (dd, J = 8.8, 2.2 Hz, 1H), 6.97 (d, J = 
2.2 Hz, 1H), 5.44-5.19 (m, 10H), 2.79-2.75 (m, 8H), 2.37 (t, J = 7.2 Hz, 2H), 2.16 (q, J = 6.9 
Hz, 2H), 2.04 (p, J = 7.2 Hz, 2H), 1.62 (p, J = 7.3 Hz, 2H), 0.94 (t, J = 7.5 Hz, 3H).13C NMR 
(75 MHz, CDCl3):  177.06, 163.58, 158.25, 157.92, 132.14, 129.08, 128.89, 128.67, 128.43, 
128.35, 128.21, 128.20, 127.98, 127.73, 127.13, 116.58, 116.17, 111.04, 103.21, 97.02, 70.52, 
28.43, 26.54, 25.77, 25.76, 25.73, 25.66, 20.68, 19.26, 14.39. HRMS calcd. for C30H34O3
[M]+ 442.2508, found 235.1011. 
3-((6Z,9Z,12Z,15Z,18Z)-heneicosa-6,9,12,15,18-pentaen-1-yn-1-yl)-7-methoxy-4H-
chromen-4-one (185b). 
To a stirred mixture of 185a (100 mg, 0.226 mmol) and anhydrous K2CO3 (47 mg, 0.339 
mmol) in dry acetone (10 ml), MeI (48 mg, 0.339 mmol) was added. The mixture was heated 
at reflux for 2 h and then allowed to cool to room temperature. The mixture was filtered and 
evaporated under reduced pressure to afford a residue that was purified by column 
chromatography (silica gel, hexane/EtOAc, 8:2) to afford 185b as yellow oil (82 mg, 80%). 
1H NMR (300 MHz, CDCl3): 8.12 (d, J = 8.9 Hz, 1H), 7.97 (s, 1H), 6.93 (dd, J = 8.9, 2.4 
Hz, 1H), 6.78 (d, J = 2.4 Hz, 1H), 5.45-5.21 (m, 10H), 3.87 (s, 3H), 2.89-2.74 (m, 8H), 2.44 
(t, J = 7.2 Hz, 2H), 2.22 (q, J = 7.1 Hz, 2H), 2.04 (p, J = 7.1 Hz, 2H), 1.67 (p, J = 7.2 Hz, 2H), 
0.94 (t, J = 7.5 Hz, 3H). 13C NMR (75 MHz, CDCl3):  175.23, 164.24, 157.80, 157.20, 
132.14, 129.19, 128.91, 128.66, 128.53, 128.33, 128.26, 128.18, 128.01, 127.75, 127.14, 
117.58, 114.89, 111.70, 100.42, 96.13, 71.00, 55.96, 28.59, 26.53, 25.80, 25.77, 25.73, 25.66, 
20.68, 19.34, 14.40. HRMS calcd. for C31H36O3 [M]+ 456.2664, found 456.2660. 
3-(Heneicos-1-yn-1-yl)-7-hydroxy-4H-chromen-4-one (186a) 
To a stirred solution of compound 184a (0.323 g, 0.87 mmol), CuI (40 mg, 0.20 mmol), 
Pd(Ph3P)2Cl2 (14 mg, 0.03 mmol) in THF (9 ml), triethylamine (0.42 ml, 3.0 mmol) was 
added, followed by addition of alkyne 180 (0.29 g, 1.00 mmol). The reaction mixture was 
allowed to stir at room temperature for 2 h. The mixture was then diluted with EtOAc (20 ml) 
and washed with satd. aq. NH4Cl. The organic solution was dried (MgSO4), filtered and 
evaporated under reduced pressure. The crude product was dissolved in MeOH/THF (1:1, 180 
ml), followed by addition of  p-toluenesulfonic acid monohydrate (4 mg, 0.021 mmol). This 
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mixture was stirred at 60 °C for 1 h and then allowed to cool to room temperature. Et3N (0.03 
ml, 0.21 mmol) was added. The mixture was evaporated to afford a residue that was purified 
by column chromatography (silica gel, hexane/EtOAc, 8.5:1.5) to yield compound 186a as 
white solid (0.314 g,   80%). 1H NMR (300 MHz, Pyr-d5):  8.39 (s, 1H), 8.33 (d, J = 8.8 Hz, 
1H), 7.14 (dd, J = 8.8, 2.3 Hz, 1H), 7.00 (d, J = 2.2 Hz, 1H), 4.98 (br s, 1H), 2.42 (t, J = 7.0 
Hz, 2H), 1.56 (dt, J= 14.0, 6.4 Hz, 2H), 1.28-1.24 (m, 32H), 0.85 (t, J = 6.6 Hz, 3H).13C NMR 
(75 MHz, Pyr-d5):  175.09, 164.54, 158.44, 158.26, 128.05, 117.04, 116.39, 111.80, 103.47, 
96.14, 72.64, 32.28 , 30.16(8 x CH2), 30.08 (2 x CH2), 29.97, 29.77, 29.60, 29.33, 29.11, 
23.09, 20.01, 14.43. HRMS calcd. for C30H44O3 [M]+ 452.3290 found 452.3287. 
3-(heneicos-1-yn-1-yl)-7-methoxy-4H-chromen-4-one (186b) 
To a stirred mixture of 186a (20 mg, 0.044 mmol) and anhydrous K2CO3 (9 mg, 0.066 mmol) 
in acetone (10 ml), MeI (9 mg, 0.066 mmol) was added. The mixture was heated at reflux for 
2 h. The resulting mixture was then cooled to room temperature, filtered and evaporated under 
reduced pressure. The residue was purified by column chromatography (silica gel, 
hexane/EtOAc, 8:2) to yield compound 186b (18 mg, 87%). 1H NMR (300 MHz, CDCl3): 
8.12 (d, J = 8.9 Hz, 1H), 7.98 (s, 1H), 6.94 ( dd, J= 8.9, 2.3 Hz, 1H), 6.78 (d, J = 2.4 Hz, 
1H)3.87 (s, 3H), 2.41 (t, , J = 7.1 Hz, 2H), 1.63-1.54 (m, 2H), 1.26-1.23 (m, 32H), 0.85 (t,, J = 
6.6 Hz, 3H).13C NMR (75 MHz, CDCl3):  175.58, 164.51, 158.09, 157.47, 128.04, 117.86, 
115.16, 112.06, 100.68, 96.88, 70.90, 56.23, 32.32, 30.10 x 8 CH2, 30.06 x 2 CH2, 29.92 , 
29.76 , 29.57, 29.38, 29.01, 23.09, 20.13, 14.51. HRMS calcd. for C31H46O3 [M]+ 466.3447, 
found 466.3443. 
3-((6Z,9Z,12Z,15Z,18Z)-heneicosa-6,9,12,15,18-pentaen-1-yn-1-yl)-5,7-dihydroxy-4H-
chromen-4-one (187a). 
To a stirred solution of compound 184b (0.260 g, 0.67 mmol), CuI (23 mg, 0.12 mmol), 
Pd(Ph3P)2Cl2 (21 mg, 0.03 mmol) in THF (9 ml), triethylamine (0.28 ml, 1.98 mmol) was 
added, followed by addition of alkyne 122 (0.28 g, 1.00 mmol). The reaction mixture was 
allowed to stir at room temperature for 2 h. The mixture was diluted with EtOAc (20 ml) and 
washed with sat. aq. NH4Cl. The organic solution was dried over MgSO4, filtered and 
evaporated under reduced pressure. The resulting crude product was then dissolved in CHCl3
(20 ml), MeOH (10 ml), followed by addition of conc. HCl (1 ml). The mixture was refluxed 
for 1 h. The reaction was then quenched with water and extracted with CHCl3 (3 x 15 ml). 
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The combined organic layers was dried (MgSO4), filtered and evaporated under reduced 
pressure to afford a residue that was purified by column chromatography (silica gel, 
hexane/EtOAc, 7:3) to yield 187a as yellow oil (0.243 g, 80%). 1H NMR (300 MHz, CDCl3): 
 12.39 (s, 1H), 7.93 (s, 1H), 6.84 (s, 1H), 6.37 (d, J = 2.2 Hz, 1H), 6.32 (d, J = 2.2 Hz, 1H), 
5.42-5.22 (m, 10H), 2.83-2.75 (m, 8H), 2.39 (t, J = 7.2 Hz, 1H), 2.18 (q, J = 7.0 Hz, 2H), 2.03 
(p, J = 7.0 Hz, 2H), 1.63 (p, J = 7.2 Hz, 2H), 0.95 (t, J = 7.5 Hz, 1H).13C NMR (75 MHz, 
CDCl3):  180.82, 163.39, 162.72, 158.32, 158.09, 132.47, 129.32, 129.28, 128.98, 128.75, 
128.67, 128.52 (2 x CH), 128.29, 127.44, 110.40, 105.66, 100.56, 97.81 , 95.00, 69.75, 28.71, 
26.80, 26.06 (2 x CH2), 26.03, 25.95, 20.98, 19.53, 14.69. HRMS calcd. for C30H34O4 [M]+ 
458.2457, found 458.2455. 
3-((6Z,9Z,12Z,15Z,18Z)-henicosa-6,9,12,15,18-pentaen-1-yn-1-yl)-5-hydroxy-7-methoxy-
4H-chromen-4-one (187b). 
To a stirred mixture of 187a (30 mg, 0.066 mmol) and anhydrous K2CO3 (14 mg, 0.10 mmol) 
in acetone (3 ml) 1 ml, MeI (14 mg, 0.10 mmol) was added. The mixture was heated at reﬂux 
for 2 h and it was subsequently cooled to room temperature, ﬁltered and evaporated under 
reduced pressure. The resulting crude product was purified by column chromatography (silica 
gel, hexane/EtOAc, 7:3) to yield compound 187a as yellow oil (24 mg, 83 %). 1H NMR (300 
MHz, CDCl3):  12.46 (s, 1H), 7.93 (s, 1H), 6.34 (s, 2H), 5.38-5.34 (m, 10H), 3.83 (s, 3H),  
2.81-2.75 (m, 8H), 2.45 (t, J = 7.1 Hz, 2H), 2.22 (q, J = 6.7 Hz, 2H), 2.05 (p, J = 7.1 Hz, 2H), 
1.67 (p, J = 7.2 Hz, 2H), 0.95 (t, J = 7.5 Hz, 3H).13C NMR (75 MHz, CDCl3):  180.55, 
166.14, 162.70, 158.02, 157.91, 132.45, 129.35, 129.33, 128.97, 128.76, 128.66, 128.51 x 
2CH, 128.29, 127.43, 110.54, 105.87, 98.93, 97.29, 93.27, 70.02 , 56.26, 28.81, 26.79, 26.09, 
26.06, 26.02, 25.95, 20.97, 19.56, 14.69. HRMS calcd. for C31H36O4 [M]+ 472.2614, found 
472.2605. 
3-(Henicos-1-yn-1-yl)-5,7-dihydroxy-4H-chromen-4-one (188a). 
To a stirred solution of compound 184b (0.26 g, 0.67 mmol), CuI (23 mg, 0.12 mmol), 
Pd(Ph3P)2Cl2 (21 mg, 0.03 mmol) in THF (9 ml), triethylamine (0.28 ml, 1.98 mmol) was 
added, followed by addition of alkyne 180 (0.29 g, 1.00 mmol). The reaction mixture was 
allowed to stir at room temperature for 2 h. The mixture was then diluted with EtOAc (20 ml) 
and washed with sat. aq. NH4Cl. The organic solution was dried over MgSO4, filtered and 
evaporated under reduced pressure using rotavapor. The resulting crude product was 
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dissolved in CH3Cl (20 ml), MeOH (10 ml), followed by addition of conc. HCl (1 ml). The 
mixture was refluxed for 1 h and then quenched with water. The mixture was then extracted 
with CHCl3 (3x15 ml). The combined organic layers was dried (MgSO4), filtered and 
evaporated under reduced pressure using to afford a residue that was purified by column 
chromatography (silica gel, hexane/EtOAc, 7:3) to afford compound 188a as white solid 
(0.258 g, 83%). 1H NMR (300 MHz, Pyr-d5):  13.26 (s, 1H), 8.42 (s, 1H), 6.70 (d, J = 2.1 
Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 5.04 (brs, 1H), 2.45 (t, J = 6.9 Hz, 2H), 1.62-1.55 (m, 2H), 
1.32-1.30 (m, 32H), 0.89 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, Pyr-d5):  180.56, 166.46, 
163.21, 159.13, 158.37, 123.97,110.25, 105.08, 100.65, 97.00, 95.21, 71.20, 32.28, 30.16(8 x 
CH2), 30.08, 29.96, 29.77, 29.57, 29.27, 29.00, 23.09, 19.96, 14.43. HRMS calcd. for 
C30H44O4 [M]+ 468.3240, found 468.3237. 
3-(Henicos-1-yn-1-yl)-5-hydroxy-7-methoxy-4H-chromen-4-one (188b) 
To a stirred mixture of 188a (30 mg, 0.064 mmol) and anhydrous K2CO3 (13 mg, 0.09 mmol) 
in acetone (3 ml), MeI (13 mg, 0.09 mmol) was added. The mixture was heated at reflux for 2 
h. The reaction mixture was then cooled to room temperature, filtered and evaporated under 
reduced pressure. The residue was purified by column chromatography (silica gel, 
hexane/EtOAc, 8:2) to yield compound 188b as yellow oil (31 mg, 90%). 1H NMR (300 
MHz, CDCl3):  12.46 (s, 1H), 7.93 (s, 1H), 6.34 (s, 2H), 3.83 (s, 3H), 2.42 (t, J = 7.2 Hz, 
2H), 1.64-1.53 (m, 2H), 1.28-1.23 (m, 32H), 0.85 (t, J = 6.6 Hz, 3H). 13C NMR (75 MHz, 
CDCl3):  180.55, 166.09, 162.65, 158.07, 157.88, 110.60, 105.84, 98.89 , 97.71, 93.22, 
69.63, 56.22, 32.32, 30.10(8 x CH2), 30.06, 30.03, 29.91, 29.76, 29.54, 29.37, 28.95, 23.09, 
20.07, 14.51. HRMS calcd.for C31H46O4 [M]+ 482.3396, found 482.3393. 
(E)-methyl dec-2-en-4-ynoate (201). 
2-Octynal (199) (1 g, 8.06 mmol) and Wittig reagent 200 (3.24 g, 9.72 mmol) in dry toluene 
(10 ml) under argon was heated at 90 oC for 10 h. The reaction mixture was cooled at room 
temperature. The solvent was evaporated under reduced pressure to afford a residue that was 
treated with Et2O (20 ml), filtered and the solvent evaporated. The resulting crude product 
was purified by column chromatography (silica gel, hexane/EtOAc, 98:2) to yield compound 
201 as yellow oil (1.20 g, 83%).  1H NMR (300 MHz, CDCl3):  6.74 (dt, J = 15.8, 2.3 Hz, 
1H), 6.12 (d, J = 15.8 Hz, 1H), 3.72 (s, 3H), 2.34 (td, J = 7.1, 2.2 Hz, 2H), 1.52 (td, J = 7.1 
Hz, 2.2 Hz, 2H), 1.33-1.27 (m, 4H), 0.88 (t, J = 7.0 Hz, 3H).13C NMR (75 MHz, CDCl3): 
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166.98, 129.04, 126.70, 101.55, 78.28, 52.09, 31.43, 28.39, 22.54, 20.13, 14.31.HRMS 
calcd. for C11H16O2 [M]+180.1150, found 180.1147. 
(E)-dec-2-en-4-yn-1-ol  (202). 
To a solution of compound 201 (0.315 g, 1.75 mmol) in dry THF (30 ml) under argon, 
diisobutyl aluminium aluminum hydride (3.5 ml, 1.0 M, 3.5 mmol) was added at room 
temperature over a period 15 min at 0 oC. The reaction mixture was allowed to warm at 
ambient temperature and stirred at this temperature for 3 h. The reaction was then quenched 
by adding 1M HCl (6 ml). The mixture allowed to stir for 30 min and then extracted with 
Et2O (3x50 ml) to afford a residue that was purified by column chromatography (silica gel, 
hexane/EtOAC, 97:3) to yield compound 202 as yellow oil (0.22 g, 82%).1H NMR (300 
MHz, CDCl3):  6.13 (dt, J = 15.8, 5.5 Hz, 1H), 5.69 (dt, J = 15.8, 2.0 Hz, 1H), 4.15 (dd, J = 
5.5, 1.7 Hz, 2H), 2.27 (td, J = 7.1, 2.2 Hz, 2H), 1.54-1.48 (m, 4H), 1.34-1.31 (m, 4H), 0.88 (t, 
J = 7.1 Hz, 3H). 13C NMR:  (75 MHz, CDCl3)  140.48, 111.77, 91.89, 78.65, 63.48, 31.47, 
28.80, 22.60, 19.75, 14.36. HRMS calcd. for C10H16O [M]+ 152.1201, found 152.1200. 
(E)-dec-2-en-4-ynal (203).  
To a solution of alcohol (0.146 g, 0.9 mmol) in dichloromethane (30 ml), manganese dioxide 
(1.67 g, 18 mmol) was added. The reaction mixture was allowed to stir at room temperature 
overnight and then the mixture was filtered. The solvent was evaporated to afford a residue 
that was purified by column chromatography (silica gel, hexane/EtOAc, 97:3) to yield 
compound 203 as yellow oil (85 mg, 90%). 1H NMR (300 MHz, CDCl3):  9.52 (d, J = 7.8 
Hz, 1H), 6.58 (dt, J = 15.8, 2.2 Hz, 1H), 6.36 (dd, J = 15.8, 7.8 Hz, 1H), 2.41 (td, J = 7.1, 2.2 
Hz, 2H), 1.61-1.52 (m, 2H), 1.37-1.33 (m, 4H), 0.89 (t, J = 7.0 Hz, 3H).13C NMR (75 MHz, 
CDCl3):  193.89, 139.35, 134.31, 107.82, 74.81, 31.44, 28.27, 22.53, 20.43, 14.31.HRMS 
calcd. for C10H14O [M]+ 150.1045, found 150.1041. 
(1E,3E)-1-iodoundeca-1,3-dien-5-yne (191a). 
To a mixture of CrCl3 (26mg, 0.165 mmol) and zinc (0.257 g, 3.96 mmol) in dry THF (7 ml), 
TMSCl (0.43 ml, 3.96 mmol) was added. The reaction mixture was allowed to stir at room (ca 
40 min) until the color of the solution turned to green, which was an indication of the 
formation of CrCl2. A mixture of aldehyde 203(49 mg, 0.33 mmol) and iodoform (0.26 g, 
0.66 mmol) in dry THF (3 ml) was added to the reaction mixture dropwise over a period 1.5 
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h. The reaction mixture became brown and was stirred at room temperature for 4 h. The 
reaction was diluted with hexane (10 ml), water (50 ml) was added. The organic layer was 
collected and then the aqueous layer was extracted with Et2O (3x50 ml). The combined 
organic layers was dried (MgSO4), filtered and evaporated to afford a residue that was 
purified by column chromatography (silica gel, hexane) to afford compound 191a as yellow 
oil (54 mg, 69%) yield. 1H NMR (300 MHz, CDCl3):  7.12-6.14 (m, 3H), 6.03-5.52 (m, 1H), 
2.30 (dtd, J = 12.0, 7.1, 2.3 Hz, 2H), 1.59-1.47 (m, 2H), 1.42-1.47 (m, 4H), 0.89 (td, J = 7.0, 
3.1 Hz, 3H).13C NMR (75 MHz, CDCl3):  144.98, 140.20, 139.83, 138.29, 117.06, 113.46, 
96.96, 83.95, 31.51, 28.69, 22.60,  20.16, 14.36. HRMS calcd. for C11H15I [M]+274.0218, 
found 274.0207. 
(E)-2-(Hex-1-en-3-yn-1-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione (236). 
To a mixture of (E)-2-Bromovinyl MIDA boronate (201) (0.2 g, 0.77 mmol), Pd(Ph3P)2Cl2
(30 mg, 0.04 mmol), CuI (90 mg, 0.47mmol,) in dry THF (20 ml) under argon, piperidine (0.3 
ml, 3 mmol) was added, followed by the addition of condensed 1-butyne 238 (0.6 ml, 
7.7mmol). The mixture was allowed to stir at room temperature for 3 h. The resulting mixture 
was diluted with EtOAc (10 ml) then filtered through short pad of silica gel using EtOAc (50 
ml) as eluent. The solvent was evaporated to afford a residue that was purified by column 
chromatography (silica gel, hexane: EtOAc, 1:1), followed by Et2O and EtOAc) to yield 
compound 236 as colorless solid (0.116  g, 69 %). 1H NMR (400 MHz, CDCl3):  6.16-5.85 
(m, 2H), 3.83 (d, J = 16.3 Hz, 2H), 3.66 (d, J = 16.4 Hz, 2H), 2.84 (s, 3H), 2.31 (qd, J = 7.5, 
2.0 Hz, 2H), 1.14 (t, J = 7.5 Hz, 3H).13C NMR (101 MHz, CDCl3):  166.79, 125.18, 94.37, 
79.65, 61.42, 46.72, 13.74, 13.11. HRMS calcd. for C11H14BNO4 [M]+ 235.1016, found 
235.1011. 
Dec-9-yn-1-ol (241). 
Lithium (0.272 g, 38.97 mmol, 6.0 equivalents) was dissolved in 1,3-diaminopropane (30 ml) 
and stirred for 30 min at room temperature. The reaction mixture was allowed to stir at 70 oC 
until the blue color had disappeared and afforded a white suspension of the lithium amide.     
t-BuOK (2.94 g, 26 mmol, 4.0 equivalents) was added. The formed yellow solution was 
stirred for 20 min at room temperature and then 2-decyne-1-ol 240 (1 g, 6.5 mmol, 1.0 
equivalent) was added to the reaction mixture over 10 min at room temperature. The reddish 
brown mixture was allowed to stir overnight at room temperature.  The reaction mixture was 
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poured into ice/water (200 ml), extracted with Et2O (3 x 50 ml) and washed with water (50 
ml), 10% HCl (50 ml) and brine (50 ml). The organic solution was dried (MgSO4). The 
solvent was evaporated to yield alkyne 241 (0.98 g, 98%), without any further purification.1H 
NMR (400 MHz, CDCl3):  3.61 (t, J = 6.6 Hz, 2H), 2.16 (td, J = 7.0, 2.6 Hz, 2H), 1.91 (t, J = 
2.7 Hz, 1H), 1.51 (dq, J = 14.8, 7.3 Hz, 4H), 1.46-1.18 (m, 8H). 13C NMR (101 MHz, 
CDCl3):  84.75, 68.09, 63.03, 32.76, 29.27, 29.05, 28.66, 28.45, 25.68, 18.39. HRMS calcd. 
for C10H18O [M]+ 154.1358, found 154.1355. 
Dec-9-ynal (242). 
To a stirred solution of alcohol 241 (0.5 g, 3.25 mmol, 1.0 eq) in dichloromethane (30 ml), 
Dess-Martin periodinane (1.65 g, 3.9 mmol, 1.2 eq) was added. The reaction was allowed to 
stir at room temperature for 1.5 h and then diluted with EtOAc (20 ml). The reaction mixture 
was washed with a mixture of sat. aq. NaHCO3 and 10% aq. sodium thiosulfate (1:1, 10 ml). 
The aqueous layer was extracted with EtOAc (2 x 30 ml). The combined solvent was washed 
with water, dried (MgSO4). The solvent was filtered and evaporated to afford a residue that 
was purified by column chromatography (silica gel, 15% EtOAc in hexane) to yield 
compound 242 as colorless oil (0.46 g, 94 %). 1H NMR (400 MHz, CDCl3):  9.74 (s, 1H), 
2.40 (td, J = 7.4, 1.8 Hz, 2H), 2.15 (dt, J = 6.8, 3.5 Hz, 2H), 1.91 (t, J = 2.7 Hz, 1H), 1.70-
1.17 (m, 12H).13C NMR (101 MHz, CDCl3):  202.85, 84.61, 68.18, 43.87, 29.00, 28.82, 
28.48, 28.35, 21.99, 18.35. HRMS calcd. for C10H18O [M]+152.1201, found 152.1118. 
2-(Non-8-yn-1-yl)-1,3-dioxolane (239). 
Aldehyde 242 (0.40 g, 2.6 mmol) in toluene (15 ml) was treated with ethylene glycol (0.30 
ml, 5.65 mmol, 2.15 eq) and a catalytic amount of  p-TsOH.  The mixture was refluxed for 8 h 
with a Dean-Stark trap and poured into a cold saturatedaqueous NaHCO3 (50 mL).  The 
organic layer was separated, washed with brine (10 ml), dried (MgSO4), and filtered.  The 
solvent was evaporated under reduced pressure, and the resulting crude product was purified 
by column chromatography (silica gel, hexane/EtOAc, 97:3) to yield compound 239 as 
colorless oil (0.45 g, 87%). 1H NMR (400 MHz, CDCl3):  4.81 (t, J = 4.8 Hz, 1H), 4.01-3.73 
(m, 4H), 2.14 (td, J = 7.1, 2.6 Hz, 2H), 1.90 (t, J = 2.6 Hz, 1H), 1.63-1.55 (m, 2H), 1.55-1.25 
(m, 10H).13C NMR (101 MHz, CDCl3):  104.65, 84.71, 68.06, 64.82, 33.87, 29.37, 28.98, 
28.61, 28.44, 24.00, 18.36.HRMS calcd. for C12H20O2 [M]+ 196.1463, found 196.1457. 
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(E)-2-(11-chloro-undec-10-en-8-yn-1-yl)-1,3-dioxolane (237). 
trans1,2-Dichloroethene 194 ( 0.94 ml, 1.80 mmol, 5 eq) and piperidine (0.57 ml, 5.86 mmol, 
3 eq) were added to a mixture of Pd(Ph3P)2Cl2 (68 mg, 0.097 mmol, 5 mol%) and CuI (74 mg, 
0.39 mmol, 20 mol%) in dry THF (10 ml) under argon. Subsequently, a solution of 2-(non-8-
yn-1- yl)-1,3-dioxolane (239) (0.38 g, 1.95 mmol) in dry THF (1 ml) was added. The reaction 
mixture was allowed to stir for 3 h at room temperature. The resulting mixture was then 
diluted with EtOAc (20 ml) then filtered through short pad of silica gel using EtOAc (50 ml) 
as eluent. The filtrate was evaporated under reduced pressure and the crude product was 
purified by column chromatography using (silica gel, hexane/EtOAc, 97:3) to yield 
compound 237 as a colorless oil (0.32 g, 64%).1H NMR (400 MHz, CDCl3):  6.51-6.41 (m, 
1H), 5.59 (dd, J = 11.9, 2.7 Hz, 1H), 4.82 (t, J = 4.9 Hz, 1H), 3.93 (d, J = 6.7 Hz, 2H), 3.83 
(d, J = 6.7 Hz, 2H), 2.30 (td, J = 7.1, 2.0 Hz, 2H), 1.63 (dt, J = 8.7, 5.2 Hz, 2H), 1.49 (q, J = 
7.1 Hz, 2H), 1.41-1.26 (m, 8H).13C NMR (101 MHz, CDCl3):  139.63, 113.19, 104.66, 
94.79, 79.88, 64.83, 33.88, 29.38, 29.01, 28.75, 28.65, 24.01, 19.67. HRMS calcd. for 
C14H21ClO2 [M]+ 256.1230, found 256.1224. 
2-((10E,12E)-heptadeca-10,12-dien-8,14-diyn-1-yl)-1,3-dioxolane (235). 
A solution of boronate 236 (32 mg, 0.14 mmol, 1.5 eq) in THF (5 ml) was treated with 1N aq. 
NaOH (1.1 ml, 5 eq) and the reaction mixture was stirred for 10 min at room temperature. 
Subsequently, Pd(PPh3)4 (10 mg, 0.009 mmol, 10 mol%) and vinyl chloride 237 (27 mg, 0.09 
mmol, 1.0 eq) were added in sequence and the temperature was increased to 60 oC. The 
resulting mixture was allowed to stir for 2 h. Then, after having cooled, the reaction mixture 
was diluted with n-hexane (10 ml), dried (MgSO4) and filtered through a short pad of silica 
gel. The filtrate was evaporated under reduced pressure and the crude product was purified by 
column chromatography (silica gel, hexane/EtOAc, 97:3) to yield compound 235 as a 
colorless oil (10 mg, 32%). 1H NMR (300 MHz, CDCl3):  6.48 (d, J = 14.6 Hz, 1H), 5.81-
5.25 (m, 3H), 4.82 (t, J = 4.8 Hz, 1H), 3.99-3.76 (m, 4H), 2.30 (ddt, J = 11.7, 7.6, 2.3 Hz, 
2H), 1.69-1.26 (m, 12H), 1.14 (t, J = 7.5 Hz, 3H).13C NMR (75 MHz, CDCl3):  140.00, 
125.80, 118.04, 113.65, 113.49, 105.05, 96.37, 95.23, 65.22, 34.27, 29.79, 29.41, 29.15, 
29.03, 24.41, 20.07, 19.70, 14.21, 13.76. HRMS calcd. for C20H42O4 [M]+ 300.2089, found 
300.2088. 
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Synthesis of mycalazol and mycalazal analogs
with potent antiproliferating activities*
Yasser M. A. Mohamed and Trond Vidar Hansen‡
Department of Pharmaceutical Chemistry, School of Pharmacy, University of Oslo,
P.O. BOX 1068, N-0316 Oslo, Norway 
Abstract: Four 2,5-disubstituted pyrrole and two 2-disubstituted thiophene analogs of the nat-
ural products mycalazol 5 and mycalazal 2 have been prepared using the Stille coupling reac-
tion. All four analogs displayed potent antiproliferating activity against several human can-
cer cell lines with IC50 values in the nanomolar range.
Keywords: antiproliferating activity; 2,5-disubstituted pyrroles; mycalazol 5; mycalazal 2;
natural products; Stille coupling. 
INTRODUCTION
Natural products are an important source for the development of new anticancer drugs [1]. Seldom is a
natural product useful directly as a drug, but more often natural products are important as lead com-
pounds for the development of a new anticancer drug. In those cases, structural–activity relationship
(SAR) studies become necessary. However, before SAR studies can be performed, the synthesis of new
analogs of the natural product of interest must be conducted [2]. Analogs are synthesized in order to
enhance the biological activity, but also for achieving selectivity toward, for example, cancer cells. The
new analogs should ideally exhibit improved pharmacokinetic as well as pharmacodynamic properties
[2].
In 1997, Salvá and co-workers [3] reported the identification of 14 structurally related 2,5-disub-
stituted pyrroles from the northeastern Atlantic sponge Mycale micracanthoxea. The compounds exhib-
ited interesting cytotoxic activity against several cancer cell lines. The presence of a saturated or an
unsaturated carbon chain attached to the pyrrole ring characterizes these natural products. Recently, we
reported the first total synthesis of mycalazol 5 (1) and mycalazal 2 (2) (Fig. 1) [4]. As part of our
 ongoing efforts on the synthesis and biological evaluation of polyunsaturated natural products [5] as
potential new anticancer agents, we herein report the synthesis and antiproliferating activity of four new
analogs of these naturally occurring 2,5-disubstituted pyrroles. The synthesis and biological evaluation
of one 2-acyl thiophene analog and one 2-alkyl thiophene analog are also presented.
Recently, it was reported by Zhou, Nagle, and co-workers that 2,5-disubstituted pyrroles, such as
4 and 5, isolated from a Mycale sponge inhibited hypoxia-inducible factor-1 (HIF-1α) in a human breast
cancer cell assay [6]. Identification of new inhibitors of HIF-1α is an attractive approach for the devel-
opment of new anticancer agents [7–9]. However, limited information on the SAR of analogs of the
mycalazol and mycalazal class of natural products has so far been published. Nabbs and Abell reported
the synthesis and cytotoxic properties data of three saturated analogs of mycalazol 11 (3) [10]. Hence,
*Paper based on a presentation made at the 18th International Conference on Organic Synthesis (ICOS-18), Bergen, Norway, 1–6
August 2010. Other presentations are published in this issue, pp. 411–731.
‡Corresponding author
based on our published synthesis of mycalazol 5 (1), we decided to prepare analogs with an unsaturated
C-20 side chain and a saturated C-20 side chain at the 2-position of the pyrrole ring. For comparison,
we also decided to prepare the 2-acyl substituted thiophene 18 and the 2-alkyl substituted thiophene
derivative 19 with a saturated C-20 side chain. These six compounds, as well as the natural products 1
and 2, were subjected to biological testing in four human cancer cell lines.
RESULTS AND DISCUSSION
Synthesis
The synthesis of analogs 13, 14, 15, and 16 started with the preparation of 5-(tri-n-butylstannyl)pyrrole-
2-carboxaldehyde (10) from commercial available pyrrole 2-carboxaldehyde 8 [11] via the known com-
pound 9a [12] (Scheme 1). First, an aqueous solution of dimethyl amine was reacted with pyrrole-2-
carboxaldehyde (8) that yielded azafulvene 9a in a quantitative yield. Compound 9a was then treated
with 2.3 equiv of n-butyl lithium followed by reaction with excess n-tributyltin chloride. This afforded
the known azafulvene derivative 9b. Then aqueous hydrolysis of 9b afforded 5-(tri-n-butylstannyl)pyr-
role-2-carboxaldehyde (10). 
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Fig. 1 Structures of mycalazol 5 (1), mycalazal 2 (2), mycalazol 11 (3), mycalazal 6 (4), mycalazal 26 (5),
eicosanoic acid (6), and eicosapentaenoic acid (7).
Scheme 1 Synthesis of stannyl pyrrole 10.
The commercially available eicosanoic acid (EA, 6) and eicosapentaenoic acid (EPA, 7) were
converted into their respective acid chlorides 11 and 12 by reaction with oxalyl chloride in methylene
chloride. The crude acid chlorides underwent Stille cross-coupling reaction [13] with the stannyl pyr-
role 10 affording compounds 13 and 14 in 76 and 71 % yields, respectively (Scheme 2).
Chemioselective reduction of the formyl group in 13 and 14 with Zn(BH4)2 [14] in THF at 0–25 °C
afforded 15 and 16 in 88 and 93 % yields, respectively.
The 2-acyl thiophene analog 18 was prepared in 84 % yield from the commercially available
2-(tri-n-butylstannyl)pyrrole 17 and acid chloride 11 again using the Stille coupling. Reduction of the
carbonyl group in 18 under standard hydrogenation conditions (Pd/C, H2, EtOH) in the presence of cat-
alytic amounts of sulfuric acid afforded thiophene 19 in 87 % yield (Scheme 3). Spectral data were in
agreement with the assigned structures. The preparation of mycalazol 5 (1) and mycalazal 2 (2) has pre-
viously been described [4].
Biological results
Mycalazol 5 (1), mycalazal 2 (2) and the four pyrrole derivatives 13, 14, 15, and 16 and the two thio-
phene analogs 18 and 19 were applied to four human cancer cell lines for the determination of their in
vitro antiproliferating activity [15]. The results are summarized in Table 1. Mycalazol 5 (1) and
mycalazal 2 (2) were the two most potent compounds in all four cell lines. In general, 1 was slightly
© 2011, IUPAC Pure Appl. Chem., Vol. 83, No. 3, pp. 489–493, 2011
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Scheme 2 Synthesis of mycalazol 5 and mycalazal 11 analogs.
Scheme 3 Synthesis of thiophene analogs 18 and 19. 
more active than 2 exhibiting IC50 values in the ranges 2.1–14.9 nM and 4.1–23.3 nM, respectively.
This is in accord with the results reported by Salvá and co-workers [3]. Analogs 13 and 14 were less
active than 1 and 2. Interestingly, the presence of both an acyl-group and a formyl-group in the 2- and
5-positions does not enhance the antiproliferating activity. The IC50 values ranged from 11.3 to 22.9 nM
for 14 and 13.0 to 31.1 nM for 13. Only a slight increase in activity was observed in all cell lines with
a polyunsaturated C-20 side chain in compound 16 compared to the saturated derivative 15. Moreover,
both compounds were less active than both mycalazol 5 (1) and mycalazal 2 (2). The IC50 values ranged
from 27.7 to 38.5 nM for 15 and 20.5 to 34.7 nM for 16. A further reduction was observed for the 2-acyl
substituted thiophene 18 with IC50 values from 45.5 to 58.7 nM. The 2-alkyl thiophene 19 was inactive
in all cancer cell assays. 
Table 1 Antiproliferating activity data of mycalazol 5 (1), mycalazal 2 (2) and analogs.
Comp. SKOVa OVCARa WM35a WM239a VEROa
1 14.9 (±2.1) 9.4 (±1.8) 2.9 (±0.9) 2.1 (±0.9) 2.1 (±0.9)
2 23.3 (±3.0) 18.0 (±2.1) 4.1 (±1.0) 4.3 (±0.8) 4.3 (±0.8)
13 31.1 (±2.3) 24.1 (±1.5) 13.0 (±1.3) 15.9 (±1.9) 15.9 (±1.9)
14 22.9 (±1.9) 21.7 (±2.8) 11.3 (±1.9) 12.1 (±2.1) 12.1 (±2.1)
15 38.1 (±2.1) 38.5 (±2.2) 36.4 (±2.1) 27.7 (±2.2) 27.7 (±2.2)
16 34.3 (±3.3) 32.7 (±4.1) 24.1 (±2.6) 20.5 (±2.9) 20.5 (±2.9)
18 49.1 (±2.1) 58.7 (±3.3) 45.5 (±3.3) 58.0 (±2.9) 58.0 (±2.9)
19 >100 >100 >100 >100 >100
aValues (nM) are means of three experiments in each cell assay; standard deviation is given in
parentheses.
The biological results reported herein indicated that the NH-pyrrole ring is important for the
observed antiproliferating activity against all four human cancer cell lines. Moreover, both mycalazol 5
(1) and mycalazal 2 (2) as well as all new analogs except 19, exhibited potent activity in the non-
cancerous VERO cell line. These results, in combination with the results from the cancer cell lines,
showed that the compounds exhibited low selectivity. Hence, other analogs of the mycalazols and
mycalzals should be prepared with antiproliferating activity toward only the cancer cell lines.
CONCLUSION
The Stille cross-coupling reaction was employed for efficient syntheses of mycalazol and mycalazal
analogs without protection of the NH-pyrrole. Moreover, the conservation of the all-Z-configuration of
the methylene-interrupted double bonds was observed for natural products 1 and 2, as well as analogs
14 and 16. In vitro antiproliferating activity against four human cancer cell lines was determined. All
four 2,5-disubstiuted pyrrole analogs revealed significant activity in both ovarian and melanoma human
cancer cell lines. The most active analog was 14. For the thiophene analogs, only compound 18 exhib-
ited antiproliferating activity. However, all analogs were less active than the natural products mycala-
zol 5 (1) and mycalazal 2 (2) and low selectivity was observed. Since inhibitors of HIF-1α continue to
be of interest as potential remedies against various cancers, further structural–activity studies will focus
on the synthesis and biological evaluation of additional analogs of mycalazol 5 (1). These efforts will
be reported in due time.
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Experimental 
Melting points were uncorrected. Analytical TLC was performed on silica gel 60 F254 Aluminium 
sheets (Merck). Flash column chromatography ws performed on silica gel 60 (40-60 μm, Fluka). 
IR spectra (4000-600 cm–1) were obtained on a Perkin-Elmer Spectrum BX series FT-IR 
spectrophotometer. NMR spectra were recorded on a Bruker Avance DPX 300 MHz 
spectrometer for 1H-NMR and 75 MHz for 13C-NMR. Coupling constants (J) are reported in 
Hertz, and chemical shifts are reported in ppm (δ) relative to CDCl3. Mass spectra were recorded 
at 70 eV with Fission’s VG pro mass spectrometer. High resolution mass spectra were performed 
with VG Prospec mass spectrometer. 
 
Chemistry 
 
Preparation of 5-(tri-n-butylstannyl)pyrrole-2-carboxyldehyde (10). 
Pyrrole-2-carboxylaldehyde 8 (1.5 g, 15.79 mmol) was dissolved in aqueous dimethylamine (40 
% wt, 20 ml) and the reaction mixture was allowed to stir for 3 h at room temperature. The 
obtained white precipitate was collected by filtration and washed with water and 1 M NaOH (10 
ml), then recrystallized from EtOAc:Et2O (1:1) to afford azafluvene dimer 9 as colorless crystals 
(2.3 g, 60%, EtOAc:Et2O). M.p. 113 oC, literature 113oC [12]. 1H-NMR (300 MHz, CDCl3): δ 
2.32 (s, 6H), 5.85 (s, 1H), 6.31 - 6.12 (m, 2H), 6.94 (dd, J = 2.7, 1.7 Hz, 1H); 13C-NMR (75 
MHz, CDCl3): δ 39.58 (2xCH3), 72.43, 106.02, 108.82, 120.01, 125.83. The major steroisomer 
(96%) has the two NMe2 group in trans relationship. To a stirred solution of azafulvene dimer 9 
(1 g, 4.09 mmol) in THF (25 ml) at -15 oC, was n-BuLi (1.6 M in hexane, 5.87 ml, 9.40 mmol) 
added. The reaction mixture stirred for 15 min at -15 oC, then for 30 min at 0 oC and 1 h at room 
temperature. The deep violet solution was cooled at -78 oC and (1.9 mg, 5.87 mmol) of n-
Bu3SnCl was added slowly. The reaction mixture was stirred for 3 h at room temperature. The 
reaction mixture was treated with aqueous AcONa (50 mL) under reflux for 3 days. After 
extraction (CH2Cl2, 20 mL) and evaporation of the solvent, the crude product was purified by 
flash chromatography (silica gel, EtOAc: n-Hexane 1:9) to yield 10 as a yellow oil (0.89 g, 57%). 
1H-NMR (300 MHz, CDCl3): δ 0.91 (t, 3H, J = 7.3 Hz), 1.13-1.63 (m, 18H), 6.43 (dd, 1H, J = 
2.3 and 3.7 Hz), 7.05 (dd, 1H, J = 2.3 and 3.7 Hz), 9.52 (s, 1H), 9.66 (br s, 1H); 13C NMR (75 
MHz, CDCl3): δ 8.20 (3xCH2), 14.00 (3xCH3), 27.62 (3xCH2), 30.71 (3xCH2), 121.51, 121.91, 
137.01, 137.01, 142.50, 178.44.   
 
Preparation of eicosanoyl chloride (11) 
Eicosanoic acid 6 (312 mg, 1 mmol) in dry CH2Cl2 (5 ml) was heated at 50 oC until all of the 
eicosanoic acid was dissolved.  Oxalayl chloride (0.15 ml, 1.2 mmol) was added to the solution 
and the mixture was allowed to stir at 50 oC for 2 h. Evaporation of the solvent gave the acid 
chloride 11 as a white solid in quantitative yield that was used directly in the next step. 
 
 
Preparation of (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoyl acid chloride (12) 
 
Oxalyl chloride (0.15 g, 1.2 mmol) was added dropwise to a stirred solution of eicosapentaenoic 
acid 7 (302 mg, 1 mmol) in dicloromethane (5 ml) at room temperature for 2 h. The solvent was 
evaporated to obtain the eicosapentaenoic acid chloride 12 as yellow oil in quantitative yield that 
was used directly in the next step. 
 
Synthesis of 5-eicosanoyl-1-pyrrole-2-carbaldehyde (13):  
The eicosanoic acid chloride 11 (170 mg, 0.50 mmol) was dissolved in dry THF (25 ml) followed 
by addition of stannyl pyrrole 10 (190 mg, 0.50 mmol. Palladium tetrakis (7.5 mg, 0.05 mmol) 
was added and the mixture was stirred at reflux under argon for 6 hrs. The reaction was quenched 
with addition of water (50 ml) and extracted with Et2O (3x50 ml). The combined organic layer 
was washed with brine and dried (MgSO4). The solvent was evaporated and the crude product 
was purified by flash chromatography (silica gel, EtOAc:n-hexane 1:9) as eluent to yield 13 as a 
white solid (0.14 g, 76%). Rf = 0.48 (n-hexane:EtOAc 1:9); m.p. 92-93 oC; IR (film): 3368, 2945, 
1681, 1654 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.85 (t, 3H, J = 6.4 Hz), 1.23-1.30 (m, 32H), 
1.64-1.70 (m, 2H), 1.94 (t, 2H, J = 7.6 Hz), 6.87 (dd, 1H, J = 2.6 and 4.0 Hz), 6.93 (dd, 1H, J = 
2.6 and 4.0 Hz), 9.68 (s, 1H), 9.98 (br s, 1H); 13C NMR (75 MHz, CDCl3): δ 14.51, 23.08, 24.93, 
29.69, 29.75, 29.78, 29.85, 29.99, 30.06, 30.09 (8 x CH2), 32.32, 39.20, 115.60, 119.96, 135.01, 
135.84, 181.12, 192.65; MS EI: m/z = 389 (M+); HRMS calcd for C25H43NO2 (M+): 389.3299, 
found 389.2938. 
  
Synthesis of 5-(5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoyl-pyrrole-2-carbaldehyde 
(14): The acid chloride 12 (160 mg, 0.50 mmol) was dissolved in dry THF (25 ml, ca 0.5 M) 
followed by addition of stannyl pyrrole 10 (190 mg, 0.50 mmol. Palladium tetrakis (7.5 mg, 0.05 
mmol) was added and the mixture was stirred at reflux under argon for 6 hrs. The reaction was 
quenched with addition of water (50 ml) and extracted with Et2O (3x50 ml). The combined 
organic layer was washed with brine and dried (MgSO4). The solvent was evaporated and the 
crude product was purified by flash chromatography (silica gel, EtOAc:n-hexane 1:9) as eluent to 
yield 14 as a yellow oil; Rf = 0.40 (n-hexane:EtOAc 1:9); IR (film): 3435, 3054, 2987, 1681, 
1657 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.94 (t, 3H, J = 7.5), 1.75-1.84 (m, 2H), 2.00-2.17 (m, 
4H), 2.76-2.85 (m, 10H), 5.24-5.36 (m, 10H), 6.86 (dd, 1H, J = 2.6 and 4.0), 6.92 (dd, 1H, J = 
2.6 and 4.0), 9.68 (s, 1H), 10.00 (br s, 1H); 13C NMR (75 MHz, CDCl3): δ 14.66, 20.95, 24.53, 
25.94, 26.04, 26.05, 26.98, 30.77, 38.40, 115.68, 119.93, 127.04, 128.25,  128.45, 128.54, 
128.57, 128.68, 128.99, 129.38, 129.43, 132.45, 135.09, 135.80, 181.18, 192.29; MS EI: (m/z) = 
379 (M+); HRMS calcd for C25H33NO2 (M+): 379.2505, found 379.2511.  
 
Synthesis of 1-(5-(hydroxymethyl)-1-pyrrol-2-yl)-eicosan-1-one  (15). 
ZnCl2 (3.4 g, 25.56 mmol) was added to sodium boronhydride (1.95 g, 52.70 mmol) in THF (50 
ml). The mixture was stirred overnight at 0-5 oC. After filtration, the resulting clear solution was 
used immediately. A freshly prepared solution of Zn(BH4)2 (2 ml, ca 0.5 M) was added drop wise 
over 5 min to a solution of 13 (60 mg, 0.15 mmol) in THF (5 ml) at room temperature. After 1 h 
of stirring, the reaction mixture was triturated with saturated NH4Cl until no more gas evolved. 
The mixture was extracted with ether. The combined organic phase was washed with saturated 
NaHCO3 (20 ml) and dried (MgSO4). After evaporation of the solvent the crude product was 
purified by flash chromatography (silica gel, EtOAc:n-hexane, 1:1) to yield 15 as a white solid 
(53 mg, 88%). Rf = 0.10 (n-hexane:EtOAc 1:1); m.p. 94-95 oC; IR (film): 3368 (br), 2944, 1654, 
1622 cm-1; 1H NMR (300 MHz, CDCl3): δ 0.86 (t, 3H, J = 7.6 Hz), 1.27-1.35 (m, 32H), 1.67-
1.74 (m, 2H), 2.79 (t, 2H, J = 7.6 Hz), 3.64 (br s, 1H), 4.71 (s, 2H), 6.12 (dd, 1H, J = 2.6 and 3.6 
Hz), 6.89 (dd, 1H, J = 2.6 and 3.6 Hz), 10.73 (br s, 1H); 13C NMR (75 MHz, CDCl3): δ 14.51, 
23.09, 26.04, 29.76, 29.81, 29.82, 29.90, 30.02, 30.05, 30.10 (8 x CH2), 32.32, 38.23, 58.25, 
109.09, 118.51, 132.00, 140.76, 192.58; MS EI: (m/z) = 391 (M+); HRMS calcd for C25H45NO2 
(M+): 391.3463, found 391.3450.  
 
Synthesis of (5Z,8Z,11Z,14Z,17Z)-1-(5-(hydroxymethyl)-1-pyrrol-2-yl)eicosa-5,8,11,14,17-
pentaen-1-one (16): A freshly prepared solution of Zn(BH4)2 (2ml) was added drop wise over 5 
min to a solution of 14 (60 mg, 0.16 mmol) in THF (5 ml) at room temperature. After 1 h of 
stirring, the reaction mixture was triturated with saturated NH4Cl until no more gas evolved. The 
mixture was extracted with ether. The combined organic phase was washed with saturated 
NaHCO3 (x ml) and dried (MgSO4). After evaporation of the solvent the crude product was 
purified by flash chromatography (silica gel, EtOAc:n-hexane, 1:1) to yield 16 as a pale yellow 
oil (56.5 mg, 93%); Rf = 0.12 (n-hexane:EtOAc 1:1); IR (film): 3436, 3055, 2988, 1652, 1629 
cm-1; 1H NMR (300 MHz, CDCl3): δ 0.95 (t, 3H, J = 7.5 Hz), 1.73-1.83 (m, 2H), 2.00-2.17 (m. 
4H), 2.74-2.82 (m, 10H), 3.15 (br t, 1H), 4.71 (d, 2H, J = 6.0 Hz), 5.25-5.39 (m, 10H), 6.13 (dd, 
1H, J = 2.6 and 3.7 Hz), 6.87 (dd, 1H, J = 2.6 and 3.7 Hz), 10.39 (s, 1H); 13C NMR (75 MHz, 
CDCl3): δ 14.51, 20.95, 23.05, 25.57, 25.94, 26.03, 27.19, 31.98, 37.54, 58.31, 108.99, 118.04, 
127.41, 128.28, 128.51 (2 x CH), 128.66 (2 x CH), 128.98, 129.22, 129.60, 132.01, 132.46, 
139.93, 191.74; MS EI: (m/z) = 381 (M+); HRMS calcd for C25H35NO2 (M+):  381.2670, found 
381.2667.  
 
Synthesis of 1-(thiophen-2-yl)eicosan-1-one (18): The eicosanoic acid chloride 11 (170 mg, 
0.50 mmol) was dissolved in THF (25 ml) and added to a solution of stannyl thiophene 16 (187 
mg, 0.50 mmol). Then the reaction mixture was refluxed under argon for 6 hrs. The reaction 
monitored by TLC. The reaction was quenched by addition of water (50 ml), and extracted by 
Et2O (3x50 ml). The combined organic layer was washed by brine then dried (MgSO4). The 
solvent was evaporated and the crude products were purified by flash chromatography using 
eluent system (n-Hexane) to yield 16 as yellow oil (84 %); IR (film): 1724, 1622 cm-1; 1H NMR 
(300 MHz, CDCl3): δ 0.85 (t, 3H, J = 7.4 Hz), 1.18-1.38 (m, 28H), 1.70-1.74 (m, 4H), 2.74 (m, 
2H), 3.34 (t, 2H, J = 7.5 Hz), 7.13 (dd, 1H, J = 3.5 and 4.0 Hz), 7.61 (d, 1H, J = 1.5 and 4.0 Hz), 
7.72 (dd, 1H, J = 1.5 and 3.5 Hz); 13C NMR (75 MHz, CDCl3): δ 14.65, 23.69, 25.91, 26.02, 
26.11, 27.19, 28.11, 28.91, 29.21, 29.51 (8 x CH2), 32.02, 37.22, 128.41, 131.28, 133.66, 144.80, 
193.1; HRMS calcd for C24H42SO (M+): 378.2956, found 378.2929.  
 
Synthesis of 2-eicosylthiophene (19): 1-(Thiophen-2-yl)eicosan-1-one 17 was dissolved in 
EtOH followed by addition of Pd/C (10.6 mg, 0.1 mmol) and  H2SO4 (0.1 ml, 3.3M). The 
reaction was allowed to stir for 14 hrs and then filtered through a plug of silica gel. Evaporation 
of the solvent afforded a yellow oil; 1H NMR (300 MHz, CDCl3): δ 0.89 (t, 3H, J = 7.4 Hz), 
1.20-1.32 (m, 32H), 1.70-1.74 (m,  4H), 2.80 (t, 2H, J = 7.4 Hz), 6.78 (dd, 1H, J = 3.6 and 4.0 
Hz), 6.89 (d, 1H, J = 1.5 and 4.0 Hz), 7.19 (dd, 1H, J = 1.5 and 4.0 Hz); 13C NMR (75 MHz, 
CDCl3): δ 14.60, 22.99, 26.01, 26.16, 26.41, 27.80, 28.61, 28.82, 29.02, 29.25 (8 x CH2), 32.32, 
38.59, 41.51, 128.21, 131.88, 133.16, 144.57; HRMS calcd for C24H44S (M+): 364.3164, found 
364.3149.  
 
Bioassay 
The method applied was a modified procedure described by Lawrence and coworkers.9 The 
human melanoma (WM35 and WM239) and ovarian (SKOV, OVCAR) cancer cell lines were 
cultivated in RPMI 1640 medium (BioWhittaker Europe, Verviers, Belgium) containing 5 % 
(melanoma)  and 10% FCS (PAA laboratories, Pasching, Austria) and 2 mM L-glutamine 
(BioWhittaker Europe, Verviers, Belgium). The WM35 and WM239 cell lines were kindly 
provided by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA) whereas the ovarian 
cell lines were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). 
5000 cells in 100 μl regular growth medium were plated per well in 96 well plates and left to 
attach overnight. Thereafter, a dilution series of compound (in 100 μl) was added. Proliferation 
was measured after 72 h following labeling of the cells with 1 μCi [3H]Thymidine (American 
Radiolabeled Chemicals, Inc, St. Louis, MO) for the last 24 h before harvesting using a 
Filtermate harvester (Packard Instrument Company, Meriden, CT). [3H]Thymidine incorporation 
was assessed in a Packard Microplate Scintillation Counter (Packard Instrument Company). 
Controls were incubated with medium containing DMSO only.  
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0316, Oslo, Norway, E-mail: t.v.hansen@farmasi.uio.no 
 
All reagents and solvents were used as purchased without further purification. Melting points were determined in 
open capillary tubes and were uncorrected. Analytical TLC was performed on silica gel 60 Merck. IR spectra (4000 
- 600 cm–1) were obtained on a Perkin-Elmer Spectrum BX series FT-IR spectrophotometer. NMR spectra were 
recorded on a Bruker Avance DPX - 300 MHZ spectrometer for 1H NMR and 75 MHZ for 13C NMR. Coupling 
constants (J) are reported in Hertz, and chemical shifts are reported in ppm () relative to CDCl3 (7.24 ppm for 1H 
and 77.40 ppm for 13C). Mass spectra were recorded at 70 eV with Fission’s VG pro. High resolution mass spectra 
were performed with VG Prospec mass spectrometer. 
 
Procedures and spectral data 
(E)- Non-1-en-3-ynyl boronic acid mida ester (3). 
B
O
O
MeN
O
O
6 7 3
82%
Pd(Ph3P)2Cl2,
CuI, piperidine,
THF, rt, 3h
B
O
O
MeN
O
O
Br+
 
To a mixture of (E)-2-bromovinylboronic acid mida ester 7 (262 mg, 1.00 mmol), Pd(Ph3P)Cl2 (35 mg, 5 mol%) 
and CuI (19 mg, 10 mol%) under Argon, dry THF (5 ml), piperidine (0.19 ml, 2.00 mmol) and 1-heptyne (6, 0.14 
ml, 1.10 mmol) were added. The reaction mixture was stirred for 3 h at room temperature. The resulting mixture was 
diluted with EtOAc (10 ml) and then filtered through a short pad of silica gel using EtOAc as eluent. The filtrate was 
evaporated under reduced pressure and the residue was purified by flash chromatography using silica gel 
(Hexane/EtOAc, 1:1, Et2O, Et2O/EtOAc, 1:1, Et2O/EtOAc, 3:7) to afford the title product as a colorless solid (0.23 
g, 82%) m.p. 110-111 oC. IR (film):  = 3054, 2986, 2125, 1770, 1602, 1550; 1H NMR (CDCl3, 300 MHz):  6.11 - 
5.86 (m, 2H), 4.05 (d, J=17.0 Hz, 2H), 3.70 (d, J=17.0 Hz, 2H), 2.81 (s, 3H), 2.26 (td, J=7.0, 1.2 Hz, 2H), 1.54 - 
1.23 (m, 1H), 0.86 (t, J=7.0 Hz, 3H); 13C NMR (CDCl3, 75 MHz):  168.98 (2 x CO), 124.88 (2 x CH), 93.24 
(CC), 80.85 (CC), 61.98 (2 x CH2), 47.57 (CH3), 31.51 (CH2), 28.75 (CH2), 22.58 (CH2), 19.81 (CH2), 14.36 
(CH3). MS (EI) m/z: 277 [M]+.    
(1E,3E)-1-Chloroundeca-1,3-dien-5-yne (10). 
 

To a solution of 3 (60 mg, 0.22 mmol, 1 eq)  in THF (5 ml), 1M NaOH (aq.) (1.1 ml, 5 eq) was added. The reaction 
mixture was stirred for 10 min at room temperature. Then Pd(PPh3)4 (24.2 mg, 0.021 mmol, 10 mol%) and trans-
1,2-dichloroethene (4, 52 mg, 0.54 mmol, 2.5 eq) were added. The temperature was increased to 60 oC and then the 
resulting mixture was allowed to stir for 2 h. The reaction mixture was cooled, diluted with n-hexane (10 ml) and 
dried (MgSO4). The reaction mixture was filtered through a short pad of silica gel and the filtrate was evaporated. 
The residue was purified by flash chromatography on silica gel (n-hexane) to afford the title product 10 as colorless 
oil (27.6 mg, 70%). IR (film):  = 3054, 2987, 2126, 1604, 1551; 1H NMR (CDCl3, 300 MHz):  6.53 - 6.16 (m, 
3H), 5.68 - 5.52 (m, 1H), 2.30 (td, J=7.1, 2.3 Hz, 2H), 1.60 - 1.14 (m, 6H), 0.88 (t, J=7.1 Hz, 3H); 13C NMR 
(CDCl3, 75 MHz):  136.27 (CH), 133.49 (CH), 122.36 (CH), 113.51 (CH), 94.96 (CC), 80.09 (CC), 31.48 
(CH2), 28.75 (CH2), 22.59 (CH2), 20.00 (CH2), 14.35 (CH3). MS (EI) m/z: 182 [M]+.    
Methyl 9-(trimethylsilyl)nona-5,8-diynoate (11).1
 
   The title compound was according to a literature procedure.1 To a mixture of Na2CO3 (1.66 g, 15.7 mmol,1.5 eq), 
CuI (1.98 g, 10.5 mmol, 1eq), n-Bu4NBr (1.01 g, 3.1 mmol, 0.3 eq) in DMF (12 ml) at -20 oC, 5-methyl hexynoate 
(9,1.32 g, 10.5 mmol, 1eq) was added, followed by addition of 3-trimethylsilyl propagyl bromide (2.38 g, 12.5 
mmol, 1.2 eq). The reaction was allowed to stir at room temperature overnight. Et2O (5 ml) was added, and filtered 
through a short pad of silica gel. Water (10 ml) was added and the mixture was extracted with Et2O (3 x 20 ml). The 
organic layer was washed with saturated NH4Cl and dried (MgSO4). The solvent was evaporated and the residue 
was purified by flash chromatography (silica gel, hexane/EtOAc, 95:5) to afford the title compound (1.97 g, 80%) as 
a colorless oil which soon turned to yellow. 1H NMR (CDCl3, 300 MHz):  3.66 (s, 3H), 3.16 (t, J=2.4 Hz, 2H), 2.42 
(t, J=7.4 Hz, 2H), 2.31 - 2.13 (m, 2H), 1.82 (q, J=7.4 Hz, 2H), 0.14 (s, 9H); 13C NMR (CDCl3, 75 MHz):  174.04 
(CO2Me), 100.88 (CC), 85.22 (CC), 80.06 (CC), 74.83 (CC), 51.93 (CH2), 33.20 (CH2), 24.21 (CH2), 18.60 
(CH2), 11.25 (CH3), 0.29 (3 x CH3). 
(Z)-Methyl 9-(trimethylsilyl)non-5-en-8-ynoate (12).1

The title compound was prepared by using a modified literature method.1 To Lindlar catalyst (Pd/CaCO3, 0.5 g, 
50%wt), MeOH (10 ml) was added and the mixture was allowed to stir under Argon at room temperature. Then the 
Argon was replaced by Hydrogen. After saturation of the catalyst, quinoline (0.54 g, 4.20 mmol, 1 eq) was added 
followed by addition of the diyne 11 (1.00 g, 4.20 mmol, 1eq). After 30 min. the reaction mixture was filtered 
through a short pad of silica gel. The solvent was evaporated and the crude was purified by flash chromatography on 
silica gel (hexane:EtOAc, 97:3) furnishing 12 as a colorless oil (0.71 g, 71%). 1H NMR (CDCl3, 300 MHz):  (ppm) 
5.53 - 5.34 (m, 2H), 3.64 (s, 3H), 2.93 (d, J=5.4 Hz, 2H), 2.29 (t, J=7.5 Hz, 2H), 2.16 - 1.98 (m, 2H), 1.70 (q, J=7.5 
Hz , 2H), 0.11 (s, 9H); 13C NMR (75 MHz, CDCl3):  174.38 (CO2Me), 130.92 (CH), 125.43 (CH), 105.50 (CC), 
84.67 (CC), 51.89 (OCH3), 33.78 (CH2), 26.88 (CH2), 24.86 (CH2), 18.74 (CH2), 0.46 (3 x CH3). 
(Z)-Methyl non-5-en-8-ynoate (5).1
 

Compound 5 was prepared by a modified literature method. 1 To a solution of 12 (0.64 g, 2.7 mmol) in MeOH (10 
ml), KF (1.56 g , 26.9 mmol) was added. The mixture was stirred for 10 h at 50 oC. After cooling the reaction 
mixture, it was diluted with water (25 ml) and extracted with Et2O (3 x 20 ml). The organic layer was washed with 
brine and dried (MgSO4). The solvent was evaporated and the crude product was purified by flash chromatography 
on silica gel (hexane:EtOAc, 98:2) to afford the title compound as a colorless oil (0.40 g, 90%). 1H NMR (300 MHz, 
CDCl3):  5.56 - 5.32 (m, 2H), 3.65 (s, 3H), 2.91 (dd, J = 5.3, 2.7 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.17 - 2.01 (m, 
2H), 1.95 (t, J = 2.7 Hz, 1H), 1.70 (q, J = 7.5 Hz, 2H); 13C NMR (75 MHz, CDCl3)  174.30 (CO2Me), 131.19 (CH), 
125.12 (CH), 83.02 (CC), 68.45 (CC), 51.90 (CH3), 33.73 (CH2), 26.82 (CH2), 24.84 (CH2), 17.22 (CH2). 
(5Z,10E)-Methyl 11-chloroundeca-5,10-dien-8-ynoate (13). 

To a mixture of Pd(Ph3P)Cl2 (2.5 mg, 0.0036 mmol, 1 mol%) and CuI (6.8 mg, 0.036 mmol, 10 mol%) in dry THF 
(5 ml) under Argon, trans 1,2-dichloroethene  (4) (0.17 ml, 1.80 mmol, 5 eq) and piperidine (0.10 ml, 1.08 mmol, 3 
eq) were added. Then (Z)-methyl non-5-en-8-ynoate (5) (60 mg, 0.36 mmol, 1 eq) in THF (1 ml) was added. The 
reaction mixture allowed to stir for 4 h at room temperature. The resulting mixture was diluted with EtOAc (10 ml) 
and then filtered through short a pad of silica gel using EtOAc as eluent. The filtrate was evaporated under reduced 
pressure and the resulting crude product was purified by flash chromatography on silica gel (hexane/EtOAc, 95:5) to 
afford the title compound 13 as a colorless oil (42 mg, 51%). IR (film):  = 3054, 2987, 2126, 1733, 1604; 1H NMR 
(300 MHz, CDCl3):  6.44 (dd, J = 13.6, 6.0 Hz, 1H), 5.88 (dt, J = 13.6, 2.4 Hz, 1H), 5.53 - 5.33 (m, 2H), 3.65 (s, 
3H), 3.01 (dd, J = 2.7, 1.6 Hz, 2H), 2.30 (t, J = 7.5 Hz, 2H), 2.07 (m, 2H), 1.70 (q, 7.5 Hz, 2H); 13C NMR (75 MHz, 
CDCl3):  174.29 (CO2Me), 131.27 (CH), 129.60 (CH), 124.85 (CH), 114.45 (CH), 91.46 (CC), 75.89 (CC), 
51.90 (OCH3), 33.71 (CH2), 26.85 (CH2), 24.82 (CH2), 18.17 (CH2); MS (EI) m/z: 226 [M]+.   
(5Z,10E,12E)-Methyl eicosa-5,10,12-trien-8,14-diynoate (2). 

Procedure 1: Suzuki-Miyaura reaction. To a solution of 3 (68 mg, 0.26 mmol, 1.5 eq) in THF (3 ml), 1 M aq. 
NaOH (0.52 ml, 3 eq) was added. The reaction mixture was allowed to stir for 15 min at room temperature then the 
reaction was quenched with saturated NH4Cl (2 ml), diluted with Et2O, extracted with (THF/Et2O, 1:1, 3 x 3 ml). 
The solvent was reduced to remaining ca 2 ml. A solution of Pd(AcO)2 (0.0083 M, 5.6 mg, 0.025 mmol) and SPhos 
(20.5 mg, 0.05 mmol) in toluene (3 ml) was allowed to stir under Argon at 65 oC for 15 min. To a mixture of 13 
(38.4 mg, 0.17 mmol, 1 eq) and K3PO4•7H2O (0.172 g, 0.51 mmol, 3 eq) in THF (2 ml), the bronic acid (2 ml) and a 
solution of Pd catalyst (0.4 ml, 2 mol% Pd) were added sequentially. The reaction mixture was allowed to stir for 16 
h at 45 oC. The mixture was cooled then diluted with EtOAc (5 ml) then filtered through short pad of silica gel. The 
solvent was evaporated to give the crude product that was purified by flash chromatography on silica gel 
(hexane/EtOAc, 98:2) to afford the compound (25 mg, 47%). IR (film):  = 3054, 2986, 2125, 1770, 1602; 1H NMR 
(300 MHz, CDCl3):  6.58 - 6.39 (m, 2H), 5.68 - 5.34 (m, 4H), 3.65 (s, 3H), 3.05 (d, J = 3.7 Hz, 2H), 2.30 (t, J = 7.4 
Hz, 4H), 2.09 (q, J = 7.5 Hz, 2H), 1.71 (q, J = 7.5 Hz, 2H), 1.50 (p, J = 7.4 Hz, 2H), 1.34 - 1.20 (m, 4H), 0.88 (t, J = 
6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3):  174.32 (CO2Me), 140.41 (CH), 139.90 (CH), 131.01 (CH), 125.27 
(CH), 113.91 (CH), 113.24 (CC), 95.45 (CC), 92.68 (CC), 80.06 (CC), 51.90 (OCH3), 33.74 (CH2), 31.48 
(CH2), 28.79 (CH2), 26.85 (CH2), 24.87 (CH2), 22.60 (CH2), 20.06 (CH2), 18.47 (CH2), 14.35 (CH3); UV, max 
(hexane, nm) = 294 (62500), 308 (65400). MS (EI) m/z: 312 [M]+.  
Procedure 2: Sonogashira cross coupling reaction.  To a mixture of Pd(Ph3P)Cl2 (12 mg, 0.017 mmol, 5 mol%) 
and CuI (6.5 mg, 0.034 mmol, 10 mol%) in THF (5 ml) under Argon, piperidine (0.10 ml,  1.05 mmol, 3 eq) and 
(1E,3E)-1-chloroundeca-1,3-dien-5-yne 10 (58 mg, 0.32 mmol, 1 eq) were added, followed by the addition of (Z)-
methyl non-5-en-8-ynoate 5 (58 mg, 0.35 mmol, 1.1 eq) in THF (1 ml). The reaction mixture was allowed to stir for 
6 h at room temperature. The resulting mixture was diluted with EtOAc (10 ml) then filtered through a short pad of 
silica gel using EtOAc as eluent. The solution was washed with saturated NH4Cl, dried (MgSO4) and evaporated 
under reduced pressure. The residue was purified by flash chromatography on silica gel (hexane/EtOAc, 98:2) to 
afford the title product 2 as a colorless oil (70 mg, 64%).  
Methyl (5Z,8Z,10E,12E, 14Z)-eicosapentaenoate (1b). 

To a suspension of Zn(Cu/Ag) (2.5 g) prepared according to a literature method2 in MeOH/H2O (6 ml, 1:1, v:v) 
followed by addition of the diyne 2 (24 mg, 0.08 mmol) dissolved in 1 ml MeOH and TMSCl (0.1 ml, 1.08  mmol) 
was added. The reaction was allowed to stir at room temperature for 1 h. The reaction mixture was filtered through a 
short pad of silica gel by eluting with MeOH. The solvent was concentrated to (1/3) of its original volume and a 
mixture of hexane/EtOAc, (1:1) (20 ml) was added. The organic layer was washed with brine (10 ml), dried 
(MgSO4) and evaporated to give a crude product that was purified by flash chromatography on silica gel 
(hexane/EtOAc, 98.5:1.5) to afford 1b as a colorless oil (21 mg, 88 %). Rf = 0.34 (EtOAc/hexane, 1:9); IR (film):  
= 3054, 2987, 1733,1601; 1H NMR (300 MHz, CDCl3)  6.47 (dd, J = 13.4, 10.8 Hz, 2H), 6.32 - 6.22 (m, 2H), 6.10 
- 5.95 (m, 2H), 5.52 - 5.26 (m, 4H), 3.65 (s, 3H), 2.91 (t, J = 6.2 Hz, 2H), 2.31 (t, J = 7.5 Hz, 2H), 2.23 - 2.03 (m, 
4H), 1.69 (p, J = 7.4 Hz, 2H), 1.45 - 1.17 (m, 6H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (75 MHz, CDCl3)  174.40 
(CO2Me), 133.81 (CH), 133.68 (CH), 132.99 (CH), 130.47 (CH), 129.67 (CH), 129.34 (CH), 129.03 (CH), 128.97 
(CH), 128.79 (CH), 128.04 (CH), 51.87 (OCH3), 33.81 (CH2), 31.87 (CH2), 29.73 (CH2), 28.32 (CH2), 26.97 (CH2), 
26.61 (CH2), 25.14 (CH2), 22.93 (CH2), 14.43 (CH2); UV max (hexane, nm): 294 (e = 56250), 305 (e = 57200), 320 
(e = 47800); (literature,3 max (hexane) = 293, 306, 321). MS (EI) m/z: 317 [M+1]+ (9), 316 [M]+ (55), 119 (32), 106 
(18), 91 (100), 79 (64), 67 (80), 55 (60). HRMS (EI) C21H32O2 requires 316.2402, found 316.2412.  
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Synthesis of Starting materials 
The following compounds wereprepared according to the literature. 
(5Z,10E,12E)-Methyl eicosa-5,10,12-trien-8,14-diynoate (5),1 (E)-methyl pentadeca-7-en-
5,9-diynoate (6),2 (E)-hexadeca-8-en-6,10-diyne (10),3 (E)-oct-6-en-4-yn-1-ol (14),4 (E)-hex-4-
en-2-yn-1-ol(16),5 (E)-pent-3-en-1-yn-1-ylbenzene (18),4 1-(4-(phenylethynyl)-phenyl)- 
ethanone (24),6 1-nitro-4-(phenylethynyl)benzene (26),7 2-(hept-1-yn-1-yl)thiophene (29).8 
 
(E)-Tetradeca-6-en-4,8-diyn-1-ol (8): 
To a mixture of Pd(Ph3P)2Cl2 (45 mg, 0.064 mmol, 5 mol%) and CuI (24 mg, 0.128 mmol, 10 
mol%) in THF (5 ml) under argon, piperidine (0.38 ml,  3.84 mmol, 3 eq) and (E)-1-chloronon-
1-en-3-yne (200 mg, 1.28 mmol, 1 eq) were added, followed by the addition of 4-pentyn-1-ol 
(323 mg, 3.84 mmol, 3 eq). The reaction mixture was allowed to stir for 3 h at room temperature. 
The resulting mixture was diluted with EtOAc (10 ml) then filtered through short pad of silica 
gel using EtOAc (30 ml) as eluent. The solution was washed with saturated ammonium chloride, 
dried over MgSO4 and evaporated under reduced pressure. The resulting crude product was 
purified by column chromatography (silica gel, hexane/EtOAc, 90:10) to afford the title product 
as a colorless oil (227 mg, 87%).  
 
 
 
 
1H NMR (300 MHz, CDCl3): δ= 5.86 (s, 2H), 3.65(t, J = 6.5 Hz, 2H), 2.44-2.35 (m, 4H), 2.29 
(td, J = 7.1, 1.6 Hz, 2H), 1.84 (q, J = 7.1 Hz, 2H), 1.53-1.48 (m, 4H), 1.36-1.28 (m, 2H), 0.88 (t, 
J = 7.1 Hz, 3H).13C NMR (75 MHz, CDCl3): δ=120.25 x 2 CH, 95.74, 93.62, 79.41, 74.89, 62.74, 
33.22, 31.47, 28.68, 22.58, 19.98, 19.46, 14.35. 
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(2E,4E)-Dodeca-2,4-dien-6-yn-1-ol (12): 
To a mixture of Pd(Ph3P)2Cl2 (25 mg, 0.036 mmol, 5 mol%) and CuI (13 mg, 0.069 mmol, 10 
mol%) in THF (3 ml) under argon, piperidine (0.204 ml,  2.07 mmol, 3 eq) and (2E,4E)-5-
bromopenta-2,4-dien-1-ol (113 mg, 0.69 mmol, 1 eq) were added, followed by the addition of 1-
heptyne (73 mg, 0.76 mmol, 1.1 eq). The reaction mixture was allowed to stir for 3 h at room 
temperature. The resulting mixture was diluted with EtOAc (5 ml) then filtered through short pad 
of silica gel using EtOAc (10 ml) as eluent. The solution was washed with saturated ammonium 
chloride, dried (MgSO4) and evaporated under reduced pressure. The resulting crude product was 
purified by column chromatography (silica gel, hexane/EtOAc, 90:10) to afford the title product 
as a colorless oil (104 mg, 84%).  
 
 
1H NMR (300 MHz, CDCl3): δ= 6.53-6.44 (m, 1H), 6.30-6.20 (m, 1H), 5.99-5.80 (m, 1H), 5.62 - 
5.40 (m, 1H), 4.20 (d, J = 5.5 Hz, 2H), 2.31 (qd, J = 7.2, 1.5 Hz, 2H), 1.54-1.30 (m, 6H), 0.88 (t, 
J = 6.8 Hz, 3H).13C NMR (75 MHz, CDCl3): δ= 139.91, 134.82, 130.85, 112.77, 94.06, 79.95, 
63.51, 31.48, 28.83, 22.60, 19.99, 14.36. 
 
3-(5-(Hept-1-yn-1-yl)thiophen-2-yl)prop-2-yn-1-ol (31):  
To a mixture of Pd(Ph3P)2Cl2 (103 mg, 0.148 mmol, 5 mol%) and CuI (57 mg, 0.296 mmol, 10 
mol%) in THF (5 ml) under argon, piperidine (0.875 ml,  8.88 mmol, 3 eq) and 2-(hept-1-yn-1-
yl)-5-iodothiophene (900 mg, 2.96 mmol, 1 eq) were added, followed by the addition of 
propargyl alcohol (497 mg, 8.88 mmol, 3 eq). The reaction mixture was allowed to stir for 3 h at 
room temperature. The resulting mixture was diluted with EtOAc (10 ml) then filtered through 
short pad of silica gel using EtOAc (30 ml) as eluent. The solution was washed with saturated 
ammonium chloride, dried (MgSO4) and evaporated under reduced pressure. The resulting crude 
product was purified by column chromatography (silica gel, hexane/EtOAc, 90:10) to afford the 
title product as a colorless oil (563 mg, 82%).  
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1H NMR (300 MHz, CDCl3): δ= 7.00 (d, J = 3.8 Hz, 1H), 6.92 (d, J = 3.8 Hz, 1H), 4.47 (s, 3H), 
2.39 (t, J = 7.1 Hz, 1H), 1.59 (td, J = 14.4, 12.9, 5.7 Hz, 1H), 1.44-1.23 (m, 2H), 0.90 (t, J = 7.1 
Hz, 1H).13C NMR (75 MHz, CDCl3): δ= 132.50, 131.06, 126.43, 122.59, 96.30, 91.64, 79.23, 
73.63, 52.12, 31.51, 28.54, 22.59, 20.08, 14.35. 
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